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PREFACE
INTRODUCTION TO DISSERTATION
Mechanisms responsible for junctional SR subdomain formation from ER have
remained undefined.

This lack of understanding hampers our ability to understand

changes in SR function in disease; such as the dramatic changes in CSQ2 structure
that we validated through a series of measurements made on control and failed heart
samples. In this research, we developed a new model of the early cardiac secretory
pathway.

By defining the individual steps of trafficking for CSQ2 and for its

transmembrane binding partners TRD and JCT, we will be able to develop new
hypotheses regarding cellular mechanisms of change.
This Dissertation research involves two studies directed at the junctional
sarcoplasmic reticulum (SR) and aspects of its dynamic cell biology. In Chapter 3, we
describe our investigations of CSQ2 purified from control and failed heart tissue. Mass
spectrometric measurements of the intact CSQ2 pool provide detailed data regarding
glycosylation and phosphorylation states in vivo.

We conclude that the observed

changes in cardiomyopathies represent alterations in intracellular trafficking within the
ER of cardiomyocytes.

Chapter 4 and 5 describe a series of studies in which we

determined the trafficking pathways of newly made junctional SR proteins as a way to
better understand the mechanisms underlying changes in protein modification. The
studies described in this Dissertation, we believe, provide important new insights into
the mechanisms of long-term change in cardiomyocytes that might underlie changes
reported in diseased heart.

xiv
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CHAPTER 1
BACKGROUND
1.1 Cardiomyocytes
1.1.1 Cardiomyocytes in the intact heart
Cardiomyocytes are specialized cells used to generate force in response to
depolarization of the heart. These cells are large (100-150 m long, 20-35 m wide),
binucleated, and surrounded by a plasma membrane known as the sarcolemma.
Invaginations of the sarcolemma at regular intervals form transverse tubules (Ttubules), which have roughly a 200 nm diameter. [1, 2]. The T-tubules are not strictly
transverse and can also communicate longitudinally, across several sarcomeres [3].
Intercalated disks spanned by gap junctions join adjacent cells and allow for rapid
conduction of action potentials; hence, all cardiomyocytes contract in synchrony. The
fundamental contractile unit in striated muscle is the sarcomere, defined as the region
confined between two Z-lines.

Chains of contractile units comprise myofibrils, and

these contain the contractile thick (myosin), thin filaments (actin and others), and titin
[4]. Contractile force is generated by interaction of actin and myosin, and regulated by
Ca2+ release from intracellular membrane stores.
1.1.2 Isolated and cultured cardiomyocytes
To explore myocardial cell biology, primary cardiomyocytes can be isolated and
cultured. Although neonatal cells are more stable, adult cardiomyocytes are preferred
for cell biological studies because the adult phenotype represents such a unique cell
system [5].

The technique for isolating viable adult ventricular myocytes was first

described in 1976 [6] and adult cells were first cultured in 1977 [7]. Several advantages
to culturing adult primary cardiomyocytes include: ability to carry out longer-term studies
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that allow manipulation of protein expression [8], examination of a single cardiomyocyte
in a controlled environment, and visualization of their structural components by a series
of

well-characterized

protein

markers.

Hence,

utilization

of

cultured

adult

cardiomyocytes allows for the extrapolation of results to the in vivo myocardium and
thus, complements intact heart preparations or whole animal studies.
1.2 Cardiac sarcoplasmic reticulum
A network of interconnecting intracellular membranes, the sarcoplasmic reticulum
(SR), is largely equivalent to the endoplasmic reticulum (ER) found in other cell types.
Besides its canonical universal role as the biosynthetic and secretory pathway,
subcompartments of cardiomyocyte ER may surround each myofibril, taking on a similar
pattern in each of the hundreds of sarcomeres in the cell (Figure 1-1).

It is this

extensive and unique sarcomeric component of the cardiomyocyte ER that gives rise to
its unique reference as SR. SR is known to play an important role dedicated to storage
and release of Ca2+ for regulating muscle contraction and excitation-contraction
coupling. SR is comprised of two distinct functional subdomains, each associated with
one of its two major functions: Ca2+ reuptake and Ca2+ release.
reuptake remains less well defined morphologically.

The site of Ca2+

The primary protein activities

associated with these two functions are the SR/ER Ca2+-ATPase (SERCA) and
ryanodine receptor (RyR), but freeze-etch studies suggest that abundant SERCA is
found across sarcomeric membrane structures, including in bilayers close to SRsarcolemma junctions [9]. RyR are a second major protein complex, and these have
almost exclusively been described extending as “feet” across the SR-sarcolemma
junctions. The Ca2+ -release complex has been studied using multiple biochemical,
biophysical, and microscopic techniques,
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Since the proteins associated with these two major activities are relatively well
characterized (discussed below), antibodies to these various proteins serve as
important markers for the two subdomains, which has permitted many investigations of
their respective localizations. The vast majority of studies to date have focused on the
Ca2+ release subdomain, and its subcellular morphology. It is clear from many studies
that Ca2+ release occurs from a specialized area of the SR that abuts the T-tubules, and
these sites appear by immunofluorescence as a series of puncta that overlie the Z-disks
of the myofilaments (Figure 1-1).
Figure 1-1. Depiction of T-tubules,
sarcoplasmic reticulum (SR) and
myofilaments in a mammalian cardiac
muscle
cell.
Each
myofibril
is
surrounded by an intermembrane
network of free SR (blue arrow) and
junctional SR cisternae (red arrow
head) that forms close to T-tubules
(green double head arrow), which
invaginate the cardiomyocyte near Zlines (Z).
1.2.1 Morphological characterization
Studies using thin section electron microscopy describe the cardiac intracellular
membrane morphology.

Throughout ventricular myocytes, the SR consists of

structurally diverse junctional, corbular and network (also referred to by many as
longitudinal or free) SR.

Spanning the region between the T-tubules, a series of

interconnected tubules form the network SR. Specialized junctions of network SR with
sarcolemmal T-tubules form the junctional SR, resulting in close juxtaposition (~15 nm)
of RyR and L-type Ca2+ channels where Ca2+ is released to initiate muscle
contraction[10-12].
A protrusion of the SR network that does not form junctions with the sarcolemma,
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but expresses RyR, is corbular SR [13, 14].

Corbular SR and non-junctional SR

(prevalent in atria), are not generally thought to be involved in depolarization-induced
Ca2+ release. Non-junctional SR is also the primary source of Ca2+ release in birds [3].
The two major functions of cardiac SR that are typically discussed, Ca2+ release and
Ca2+

reuptake,

are

therefore

not

necessarily

synonymous

with

the

two

subcompartments of junctional and free SR. The various terminologies reported to date
are descriptive of the overall sarcomeric morphology, but more detailed morphological
descriptions may not be warranted until a better understanding of the relationship
between SR and the biosynthetic/secretory pathway can be established. Even less
clear is how junctional SR and free SR subcompartments are maintained as dynamic
subcompartments of the cardiomyocyte secretory pathway.
1.2.2 SR and ER markers
The ER is a multifunctional organelle in all cells, and the vast majority of proteins
are ubiquitously present in all cell types. In cell types other than muscle, ER is probably
considered more for its roles in protein biosynthesis and secretion. Among the more
abundant proteins found in all cells are a group of luminal resident proteins that can be
generally referred to as "reticuloplasmins” [15, 16]. Whereas luminal proteins should be
secreted through bulk flow, the reticuloplasmins are actually retained in the ER. Over
time, it has became understood that most, if not all, of these reticuloplasmins are
involved in the folding of other proteins inside the secretory pathway. This function has
become generally known as "chaperone" activity.

The prototypical member of the

family is GRP78 (glucose-regulated protein, MW 78 kDa), also commonly known as the
protein BiP (Binding-immunoglobulin protein), named for its role in assisting folding of
antibody molecules in the B-cell ER [17]. GRP78 may have a wide role in folding
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nascent polypeptides as they are translated, serving as a template upon which proteins
fold in conjunction with the aqueous environment of the ER lumen. With the cloning of
several of these ER resident proteins, it was discovered that a common C-terminus
tetrapeptide (-KDEL) was responsible for its ER retention, and a KDEL receptor(s) is
now well characterized that retrieves these chaperones back to ER [18]. These findings
helped lead to the understanding of basic cell biology, as it was discovered that a
retrograde trafficking pathway was present in all cells (see Section 1.4.1).
Myocyte ER/SR contains both the common ER reticuloplasmins (Cala and Jones
1994) along with similar myocyte specific proteins, calsequestrin (CSQ), sarcaluminin,
and histidine-enriched Ca2+-binding protein [16]. CSQ alone is enriched and localized to
the junctional SR subcompartment.

None of the myocyte enriched luminal ER/SR

proteins, however, contain the KDEL retrieval sequence, and so the mechanisms for
their ER/SR enrichment have not been understood. In the case of CSQ, data suggests
that it is retained in particular subcompartments due to its unique and subcompartmentdependent Ca2+-dependent polymerization [19].

Comparable mechanisms may be

responsible for the concentration of sarcaluminin and histidine-enriched Ca2+-binding
protein in free SR. Because of the abundance of the reticuloplasmins in the ER and
SR, they are often used as protein markers of ER and SR.
The locations within the cardiac ER in which protein biosynthesis occurs, and
areas from which SR proteins are trafficked to ER subdomains (e.g. free versus
junctional SR) have remained largely undefined. Studies have shown that diffusion of
Ca2+ occurs between ER and SR compartments suggesting that as a Ca2+-handling
system, there exists a breadth of functional domains across the biosynthetic/secretory
pathway [20].
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1.3 Proteins involved in Ca2+ homeostasis
1.3.1 Ca2+ homeostasis in the cardiomyocyte
Rises in the levels of intracellular Ca2+ in the cytoplasm ([Ca2+] in) during systole
are highly regulated, and regulation of Ca2+ cycling is fundamental for achieving
maximal contraction.

When plasmalemma and T-tubules are depolarized, a Ca2+

current flows through the L-type Ca2+ channels. The Ca2+ that enters the cell through
the L-type Ca2+ channels (trigger Ca2+) as a result of depolarization, binds to the RyR,
and triggers the release of a larger flux of Ca2+ (activator Ca2+) from the SR into the
cytoplasm. This process is termed Ca2+ -induced Ca2+ release [4, 21] (Figure1-2). The
magnitude of Ca2+ release depends on the rate of filling of the SR with Ca2+, the time
interval between successive release events, and the magnitude of the trigger Ca2+ [22].
The rise and fall of Ca2+ that precedes every contraction is known as the Ca2+ transient.
Figure 1-2. Schematic diagram of junctional SR
with T-tubule and the Ca2+-induced Ca2+
release process. The protein transmembrane
components of junctional SR: triadin (TRD),
junctin (JCT) and luminal calsequestrin (CSQ)
bound to Ca2+ (red spheres) associated with
the Ca2+ -release channel (ryanodine receptor,
RyR2). Upon depolarization Ca2+ enters
through the L-type Ca2+ channel, triggers the
release Ca2+ from the SR through RyR, a
process known as Ca2+ induced Ca2+ release,
leading to contraction. During relaxation,
SR/ER Ca2+ ATPase (SERCA) reuptakes Ca2+ to restore the Ca2+ levels in SR
(Modified from [26].
Ca2+ transients lead to Ca2+ binding to troponin C (Km~0.1 μM) [23] inducing
subsequent conformational changes to activate actinomyosin ATPase, which result in
development of force. With activation of striated muscles, the troponin-tropomyosin
complex on the thin actin filaments transduces chemical energy into mechanical force
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[24] and exposes myosin binding sites, thus, allowing formation of cross bridges,
conversion of ATP chemical energy into force, sliding of the filaments, and shortening of
the sarcomeres [25].
The released Ca2+ is removed from the myofilaments and cytosol, into the SR
lumen by SERCA, into the extracellular space by plasma membrane Na+,Ca2+exchanger and plasma membrane Ca2+-ATPase, or into the mitochondria via a Ca2+
uniporter. Over the course of many depolarizations, in order for the cell to remain in a
steady state with respect to cellular Ca2+ balance, the efflux and influx of Ca2+ must
remain equal [4].
1.3.2 Major proteins of the Ca2+ -release complex
A quaternary complex of four proteins: RyR, triadin (TRD), junctin (JCT) and
CSQ, is thought to be primarily involved in the coordinated operation of Ca2+ release,
which has been proposed based on immunoprecipitation and fusion-protein pull down
assays [27]. Physical coupling of CSQ, TRD and JCT modify the resting and voltageactivated Ca2+ release through RyR, based on junctional SR Ca2+ load, suggesting that
these proteins play an active role in relaying information to RyR about the Ca2+ load in
the SR [28]. Other studies, including studies of TRD and JCT knockout mice, have
suggested that these proteins may play a more structural role. The known problem with
studies of transgenic and knockout mice has been the coordinated changes in other
junctional SR proteins (section 1.6.1)
RyRs mediate the release of Ca2+ from the SR, which is an essential step in
cardiac muscle contraction [29]. The RyR is a homotetramer, with a predicted size of
564 kDa in humans, encoded in mammals by three genes with strong sequence
homology between the isoforms: RYR1 (first to be sequenced and cloned in 1989) [30]
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is expressed in skeletal muscle, RYR2 in cardiac muscle [31], and RYR3 in smooth
muscle and the brain [32]. Between the T-tubule and terminal cisterna membrane, the
cytoplasmic domain of RyR2 forms a major part of the junctional complex [33].
In cardiac muscle, mutations in the RYR2 gene are associated with the dominant
genetic form of catecholaminergic polymorphic ventricular tachycardia (CPVT), a
familial arrythmogenic disease that manifests in childhood and adolescence [34] and is
characterized by syncope and sudden death following exercise and emotional stress.
RYR2 mutations result in “leaky” RyR2 channels by yet unknown mechanisms. The
inappropriate Ca2+ release results in increased Na2+, Ca2+ exchanger activity, which
depolarizes the cell membrane, giving rise to delayed after depolarizations [35].
Mutations in the RYR2 gene are also associated with stress-induced polymorphic
ventricular tachycardia and arrhythmogenic right ventricular dysplasia [36].
1.4 Protein: biosynthesis and trafficking
1.4.1 Protein synthesis and nascent polypeptide folding
Protein translation from mRNA is carried out on ribosomes. Large (60S) and
small (40S) ribosomal subunits assemble at the AUG codon of mRNAs at the 5’-end
and disassemble at the UAG/UGA/UAA stop codons at the 3’-end. Cytosolic, nuclear
and peroxisomal proteins are synthesized on cytosolic ribosomes [37]. However, during
translation, short hydrophobic peptide signal sequences direct a subset of nascent
polypeptides to assemble on ribosomes that are bound to the ER. Proteins translated
on rough ER include those destined for the secretory and endocytic compartments (ER,
Golgi, endosomes and lysosomes), for the plasma membrane and for secretion to the
extracellular space. The signal sequences for these cellular proteins bind the signal
recognition particle in the cytoplasm, thus slowing down chain elongation [38, 39] until
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the ribosome engages a proteinacous channel, the translocon, formed by two Sec61αβγ
heterotrimeric complexes at the ER membrane [40, 41].

With the formation of a

translocon, the protein synthesis is resumed, the short hydrophobic signal sequence
may then be removed (for some proteins such as CSQ2), and nascent chains cotranslationally enter the ER lumen [42].
1.4.2 Co-translational asparagine (N)-linked glycosylation
The most prominent modification of secretory proteins is N-linked glycosylation,
which occurs for a very high percentage of membrane and secreted proteins [43].
Oligosaccharyl transferase (OST) transfers preassembled glycans, composed of three
glucoses, nine mannoses, and two N-acetyl glucosamine residues (GlcNAc2Man9Glc3),
from a lipid pyrophosphate donor in the ER membrane, dolichol-PP, to a nascent
polypeptide chain [44].

The transfer to the consensus sequence Asn-X-Ser/Thr

generally occurs co-translationally, once it has emerged 12-14 amino acids (30-40 Å),
aligning the Asn with the active site of OST in the ER lumen [45]. An inhibitor of Nlinked glycosylation, tunicamycin, leads to improper or incomplete folding, and failure to
reach native conformation for proteins that do not pass ER quality control [46]. These
proteins are retained in the ER [47], and eventually degraded [48], a process termed ER
associated degradation.

A mature properly folded protein contains the glycan

GlcNAc2Man9, but this glycan will be reliably and predictably trimmed and modified as it
traverses the secretory pathway.
1.4.3 Post-translational modification of the (N)-linked glycans
Early quality control mechanisms are involved in the trimming of glucose from ER
glycoproteins. The enzyme glucosidase I removes the first glucose of the glycan core,
followed by the removal of the second glucose by glucosidase II. Molecular chaperones
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known also as mammalian lectins (such as calnexin and calreticulin, discussed Section
1.4.1) can bind to the monoglucosylated core of the glycoprotein, exposing it to a thioldisulfide oxidoreductase, ERp57, for proper disulfide bond formation during the on going
folding process. Glucosidase II removes the remaining glucose residues to release the
bound chains from calnexin and calreticulin.

Incompletely folded proteins get

reglucosylated by UDP-Glc: glycoprotein glucosyltransferase, which serves as a folding
sensor until the glycoprotein is properly folded or degraded [49].
Removal of mannose residues occurs first by ER α1,2-mannosidase I [50, 51], a
class I mannosidase [52], which catalyzes the first mannose trimming step concurrently
or immediately following glucose trimming. ER α1,2-mannosidase I yield a specific
Man8GlcNAc2 isomer from Man9GlcNAc2, by cleaving a single α1,2-mannose residue.
The enzyme is inhibited by kifunesine and 1-deoxymannojirimycin [52].

In rat

hepatocytes and several other mammalian cell lines, an additional mannosidase
resistant to kifunesine, termed ER α1,2-mannosidase II, has been identified and shown
to produce a Man8GlcNAc2 isomer, distinct from that of ER α1,2-mannosidase I [51,
53].
It is known that CSQ2 undergoes extensive mannose trimming from Glc2Man9
(Man9) down to Man3-4 [54, 55]. However, these authors have argued that post-ER
glycan trimming of CSQ2 would be expected to add terminal GlcNAc to the CSQ2
protein (Figure 1-3).

The fact that CSQ2 molecules do not contain any additional

sugars, but instead only undergoes mannose trimming is consistent with the idea that
CSQ2 molecules never leave the ER, and that only ER α-1,2 mannosidase is expected
to act upon CSQ2. Characterization of mannosidases in individual cell types has not
been carried out, and little data exist on the distribution of mannosidases in myocytes,
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and so the connections between CSQ2 glycan structure and its intracellular trafficking
remain uncertain.

Figure 1-3. N-linked glycan biosynthesis and CSQ2 glycan trimming along the secretory
pathway. From right to left: glycan synthesis begins at the cytoplasmic side of the ER
membrane and is then flipped to the luminal side of the membrane. Once the formation
of the core oligosaccharide (Glc3Man9GlcNAc2) is complete, the enzyme OST (not
shown) catalyzes the glycosylation of the Asn residue in the nascent growing peptide.
When the glycoprotein has properly folded (grey oval) the process of mannose trimming
occurs by intracellular mannosidases as the protein traffics through the ER and Golgi.
The glycan of CSQ2 is highly mannose trimmed contains only a variable number of
terminal Man residues, and no additional sugars are added, indicating that it does not
reach the Golgi, but is retained within junctional SR to perform its physiological function.
(Modified from [43]
1.4.4 Rough ER and smooth ER
The ER is a membrane protein biosynthesis and maturation compartment
topologically equivalent to the extracellular milieu [56]. It is classically subdivided into
rough ER areas that are sheet-like and ribosome studded and smooth ER that is more
tubular in structure.

ER domains are continuous, forming an intricate network

continuously undergoing rearrangements, composed of fenestrated cisternae and
anastomosing tubules through most of the cytoplasm [57].
Rough ER a highly dynamic part of the ER organelle marked by the site of
protein assembly and includes the translocon, a large complex of proteins that make up
the entry point into the secretory pathway. As discussed above (section 1.2.2), high
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concentrations of molecular chaperones in the ER are thought to assist protein
maturation and prevent unfolded chain aggregation. Rough ER contains homologs of
classical chaperone members of the Hsp70 and Hsp90 family, namely GRP78/BiP [58]
and GRP94 [59].

There are many other chaperones including lectin-like molecular

chaperones, such as calnexin, calreticulin and calmegin [60], which recognize the core
oligosaccharide on nascent proteins, and further assist in proper folding of ER
glycoproteins. Resident ER luminal proteins discussed above, such as GRP78/BiP,
GRP94 and protein disulfide isomerase, which covalently modifies newly synthesized
proteins, share a common carboxyl-terminal tetrapeptide sequence, the KDEL motif,
which is necessary for retention of luminal ER proteins and sufficient to cause a
normally secreted protein to be retained [61]. Retrograde transport of KDEL containing
proteins, from the intermediate compartment and the cis Golgi, is mediated by a
membrane-bound KDEL receptor [62].
1.4.5 ER exit sites and the intermediate compartment
A great deal of research over the past 10-20 years has established a basic
mechanism by which folded proteins exit the ER to continue across more distal
compartments of the secretory pathway. Transitional ER or ER exit sites form at small
ribosome free regions within the rough ER from which cytosolic coat protein II (COPII)
vesicles arise [63, 64]. COPII vesicles package properly folded and assembled proteins
and transport them out of the ER into the Golgi-directed pathways. A COPII coated bud
that transport cargo anterogradely, is initially formed by Sar1p recruited to the ER
membrane followed by Sec23-Sec24p and finally Sec12-Sec31p [65].

These early

proteins of the ER exit apparatus, which are recruited to ER exit sites, are often used as
markers.

Sec23 has been used as a marker for ER exit sites in cultured
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cardiomyocytes [66]. In the adult cardiomyocyte, it remains to be established where ER
exit sites are found, and whether SR formation from ER might require ER exit.
These COPII transport vesicles fuse to generate an ER-Golgi intermediate
compartment (ERGIC) in mammalian cells. While the ERGIC may consist of discrete
intracellular structures, it has little functional interest, other than its role as a step that is
both post-ER and pre-Golgi.

Once in Golgi, proteins are transported between

compartments via COPI coated vesicles [67].
1.4.6 Golgi
COPII vesicles exit the ER to transfer lipid and membrane protein to cis Golgi
cisternae. An important and established activity of the Golgi is the modification of glycan
moieties, which also serves as a marker of the transfer of a glycoprotein from the ER to
the Golgi and beyond. Numerous studies over time have focused on the processing of
N-linked glycoproteins continues in the Golgi. In addition, glycan modifying enzymes
such as glycosyltransferases, glycosidases, and nucleotide sugar transporters are
present in a defined manner within Golgi compartments such that each acts
consecutively on specific substrate(s) generated earlier in the pathway.
GlcNAc moieties are commonly added to free hydroxyl termini of N-linked
glycans by the enzyme GlcNAc transferase. While this modification is likely to involve
widespread changes in the functions of individual glycoproteins, its determination in
individual proteins is often used by scientists to establish basic trafficking steps.
Terminal GlcNAc moieties are thought to promote resistance to the enzyme
endoglycosidase H, compared to high mannose oligosaccharides added in the ER.
Cisternal migration moves proteins destined to be secreted to the trans face of the Golgi
and subsequently into a complex network of vesicles, termed trans Golgi network
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(TGN).

The TGN contains multiple sorting domains and produces clathrin-coated

vesicles, but not COPI vesicles, whereas earlier Golgi cisternae produce COPI vesicles.
In addition to serving as the exit face of the Golgi, the TGN is the interface between the
Golgi and the endocytic system. Clathrin cooperates with adaptors to produce vesicles
that carry certain cargoes from the TGN to endosomes [68]. Secretory cargoes are
delivered from the TGN to the plasma membrane by a variety of routes. Therefore,
although protein N-linked glycosylation and other post-translational modifications in the
various organelles are of fundamental importance in protein function in the cell, the
experience gained has established glycoproteins as reliable measures of protein
trafficking
1.4.7 Protein trafficking through the cardiac secretory pathway
For proteins to exert their functions, proper subcellular localization is essential.
Human diseases have been linked to aberrant localization of proteins caused by
dysregulation of protein trafficking [69]. Basic anterograde flow through the secretory
pathway involves proteins within membrane vesicles moving along default cytoskeletal
pathways, either to be secreted (the case for luminal proteins) or to plasma membrane
(for transmembrane proteins).
Yet, the intracellular membrane trafficking pathways and targeting mechanisms
involved in the final localization of junctional SR proteins remain unknown. One reason
for this is the fact that cardiomyocytes are not the subject of wide study of cell biologists
due to their unique structure. Meanwhile, cardiac SR biologists have not investigated
protein trafficking due in large part to the enormous effort and expertise of laboratories
in studying the details of the Ca2+ release event, at the cost of ignoring the longer-term
changes that would occur with changes in cell biology. Given that cardiac pathologies,
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and loss of contractile strength in the myocardium, are likely to involve more chronic
cellular changes, these deficits in understanding form critical needs for research.
1.5 Junctional sarcoplasmic reticulum proteins
1.5.1 Calsequestrin
CSQ is an abundant myocyte protein, and major Ca2+-binding protein in the SR
lumen of cardiac and skeletal muscle. The fast-twitch skeletal muscle isoform (CSQ1)
was first discovered in 1971 [70, 71] and is encoded by CASQ1 gene [72]. The protein
in heart, encoded by CASQ2 gene [73], was not discovered until 1983.

The two

sequences exhibit 65% identity (Figure 1-4), and both are highly acidic proteins
(isoelectric point, pI ~ 4), due to more than 37% Asp and Glu residues in the sequence.

Figure 1-4. Human CSQ amino acid sequences. Sequences of human cardiac (black)
and skeletal (red) muscle CSQ isoforms are 65% identical. The site of N-linked
glycosylation (purple shaded box) is conserved in both isoforms. A specific cardiac
isoform tail (cyan shaded box) contains two CK2-sensitive serine (S) phosphorylation
sites in humans (NCBI database). CSQ1, like CSQ2, undergoes glycosylation on
316
Asn. Because it does not contain the unique C-terminus of CSQ2, it is not
phosphorylated in vivo. It can be phosphorylated in vitro by protein kinase CK2 on
Thr373, a site that is not phosphorylated in vivo [74].

16
CSQ1 was originally discovered as a Ca2+ -binding protein component of muscle
microsomes, localized to the lumen of the skeletal muscle SR membrane. The mass of
the protein is similar for CSQ1 and CSQ2, having an approximate molecular weight of
42,000 Da. Both CSQ1 and CSQ2 migrate aberrantly on SDS-gels (Laemmli reagents),
with CSQ1 migrating as if a 63 kDa protein, while CSQ2 runs at 55 kDa.

These

aberrant mobilities, related to the low SDS-binding of the protein, contributed to the idea
prior to 1983 that CSQ did not exist in the heart. When CSQ1 and CSQ2 are compared
form the same species, CSQ1 is always slightly smaller than CSQ2 because it lacks a
20-25 amino acid C-terminus. CSQ1 is exclusively found in fast-twitch (type II) muscle
fibers, while CSQ2 exists in slow-twitch fibers [75].
The three dimensional structure of CSQ was first reported by Wang et al
(Figure1-5), showing that the monomeric form of CSQ is made of three domains; I
(residues 12-124), II (residues 125-228) and III (residues 229-352), which are nearly
highly similar to the functional topology of bacterial thioredoxin, however, CSQ has not
been shown to exhibit thioredoxin activity itself. Each CSQ domain consists of four αhelices that line (two on each side) a hydrophobic core, consisting of five β-sheets. The
domains are connected by short sequences, which along with the secondary structural
elements (α-helices), consist of acidic residues that mark the overall protein as
hydrophilic [76].
Kang and co-workers [77] have also compared the surface charge densities for
CSQ1 and CSQ2 and shown clear differences that may account for differences in their
polymerization characteristics (section 1.5.1.1.1). These differences, however, cannot
be immediately translated into differences in their biochemistry and biology because
CSQ-interaction proteins (for example, TRD and RyR) are also generally tissue specific,
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as is the structure of the sarcomeric SR compartments.
Figure 1-5. Ribbon diagram of CSQ
structure.
Monomeric
CSQ2
consists
of three domains, with the
phosphate molecules (red triangle)
schematically attached to serine
residues 378, 382 and 386 in the
(canine) cardiac-specific tail (red
rectangle). The glycan is also
schematized: 9 mannoses (blue
circles) and 2 GlcNAc (purple
squares) is attached to Asn316
(Modified from [76]).
1.5.1.1 Cardiac muscle calsequestrin (CSQ2)
CSQ2 is a major protein constituent of junctional SR in hearts that functions in
Ca2+ release through its effects on the RyR2 via the two transmembrane proteins TRD
and JCT [78-80]. In spite of decades of research, the functional role of CSQ2 in the
heart remains unknown. It was long thought to act as a Ca2+ buffer based upon its
ability to bind very large amounts of Ca2+ in vitro (30-50 mol Ca2+/mol CSQ), however,
studies of CSQ2 depletion in mice showed that levels of SR-releasable Ca2+ were not
altered. Studies described in this dissertation are not meant to determine the function of
CSQ2, however, elucidation of novel functions of its cell biology, in combination with an
examination of its changes in structure in animals with heart failure, offer interesting
new insights into its possible role in maintaining structural features of the
cardiomyocyte.
1.5.1.1.1 Ca2+ binding and polymerization
CSQ2 undertakes major changes in structure upon Ca2+ binding, and converts
from a “sticky” conformation, which binds stably to phenylagarose in micromolar Ca2+, to
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a hydrophilic conformation in millimolar Ca2+, which causes it to immediately unlatch
from phenylagarose (Cala and Jones, 1983).

This Ca2+-dependent conformational

change is widely used to purify CSQ2 from crude extracts (Cala and Jones, 1983;
Jacob et al, 2012).

Cloning of CASQ revealed that the encoded protein does not

contain a distinct Ca2+ binding domain as part of its secondary structure. From the
crystal structure, it was determined that Ca2+ binds to CSQ2 through electrostatic
attractions to negatively charged residues that are, exposed on the surfaces. At low
Ca2+ concentration CSQ2 is present as a soluble monomer. As the Ca2+ concentration
increases, front-to-front surface interactions occur, followed by back-to-back surface
interactions (Figure 1-6) as more Ca2+ is required to shield the negatively charged
residues present at the C-terminus [77].
The segregation of CSQ2 to junctional SR has been hypothetically accounted for
by TRD and JCT transmembrane proteins restricted to junctional SR [27, 81-83].
However, overexpression studies of CSQ in non-muscle cells show clearly that
polymerization can determine localization [19, 84]. CSQ2 is very efficiently retained
within the ER lumen of all non-muscle cells examined to date. Its strict localization is
confirmed by its glycan structure, which contains only Man9 and Man8 glycans.
Insertion of epitope-tags was found to reduce ER retention compared to wild-type
CSQ2, suggesting that these disrupted forms have undergone a loss of the sequencespecific polymerization that is necessary for proper localization [84]. Finally, CSQ1
does not concentrate in the ER of non-muscle cells, instead CSQ1 efficiently
polymerizes along microtubules (MTs) that emanate from the microtubule-organizing
center. CSQ1 glycans undergo a more substantial mannose trimming (Man 5-9). Thus,
CSQ2 and CSQ1 each polymerize, but they concentrate in either ER or ERGIC,
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respectively [19]. It is hypothesized that in normal heart, CSQ2 is also retained in
junctional SR by this subcompartment-specific polymerization [85].
Figure 1-6. CSQ polymerization
model. A representation of face-toface
(through
N-terminal
arm)
interactions of CSQ monomers,
followed by back-to-back interactions
(through C-terminal tail), as Ca2+
concentration
increases.
CSQ
eventually forms a linear polymer with
the front-to-front and back-to-back
interactions (Modified from [86]
1.5.1.1.2 N-linked glycosylation
N-linked glycosylation (section 1.4.2) of CSQ2 and CSQ1 occurs on Asn316
(Figure1-3 and 1-4), which is a conserved residue among species and glycoforms [87].
In non-muscle cells, CSQ2 exists in two glycoforms (Man8- and Man9-GlcNAc2);
however, CSQ2 purified from tissue (native) exists in a larger range of glycoforms
(Man1-4GlcNAc2), exhibiting a high degree of mannose trimming compared to most
proteins [49, 54], suggesting that CSQ2 remains inside the classical mammalian ER
compartments, where mannosidases are thought to be involved in glycan trimming
(section 1.4.3).

It is therefore expected that CSQ2 does not traffic to early Golgi

compartments, because GlcNAc residues would otherwise be expected to be present
on CSQ2 glycans.
The discovery that CSQ2 glycan structure is reproducibly altered in heart tissue
from beagles induced into failure by tachypacing [55] suggested that CSQ2 trafficking
was altered. The CSQ2 glycan present in failed hearts are comprised of two general
structures: those with relatively standard, highly trimmed structures (Man4-7), and a
new population of molecules not present in normal dog heart tissue. These new glycan
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structures show a lack of mannose trimming (Man9,8) expected for newly made
proteins in the ER (discussed in Chapter 3).
1.5.1.1.3 Phosphorylation by protein kinase CK2
The carboxyl terminus of canine CSQ2 molecules extends an additional 20-25
amino acids from the corresponding CSQ1 sequence (Figure 1-4). This cardiac-specific
tail is highly phosphorylated in vivo by protein kinase CK2 (formerly casein kinase II), on
a cluster of three serine residues (Ser

378,382,386

) in the canine form of CSQ2, but two

serine residues in other species (Table 1-1) [66, 74].

Consisting of two tightly

connected β subunits and two α/α’ subunits, protein kinase CK2 is present in all
eukaryotic cells [88].
The presence of phosphate on purified CSQ2 has been shown by multiple
experimental approaches [54, 74], but the clearest indication is the presence of mass
isoforms that differ only in phosphate content. Following removal of the CSQ2 glycan
from purified CSQ2 using endoglycosidase H, mass spectrometry of intact CSQ2
protein from heart tissue is composed of only four mass peaks, corresponding to 0, 1, 2,
or 3 phosphates, each differing by about 81 Da. The stoichiometry of canine CSQ2
phosphorylation is ~1.5 mol Pi/mol CSQ, but the phosphates are not evenly distributed
among CSQ2 molecules. CSQ2 is thought to undergo constitutive phosphorylation in
the early secretory pathway compartments and dephosphorylation in distal ones [89].
Phosphorylation has been hypothesized to occur in the rough ER, due to the fact that
higher phosphorylation levels were observed in the glycoforms characteristic of proximal
secretory compartments [89].
In contrast to more commonly studied hormone-mediated phosphorylation
reactions, CSQ2 phosphorylation by CK2 has been hypothesized to result from a
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process that occurs co-translationally. The data that supports this hypothesis is as
follows: 1) CK2 acts as the CSQ2 kinase in intact cells, but can theoretically only colocalize with CSQ2 prior to translocation across the ER during its biosynthesis [66], 2)
CSQ2 phosphorylation is maximal for CSQ2 molecules with unprocessed glycans, and
decreases in relation to extent of mannosidase processing [89] and 3) phosphorylation
in situ is only measurable when CSQ2 is highly expressed under cytomegalovirus
(CMV) promoter, consistent with the requirement for a co-translational reaction [89].
This phosphorylation reaction has been validated by another lab [90], but has primarily
been studied by the Cala laboratory.
Table 1-1. CK2 sensitive phosphorylation-sites present in the carboxyl-terminal tail of
CSQ2.

Sequences from the C-terminal cardiac specific tail are listed, with serine residues
(S) as the sites phosphorylated by CK2 for different species. For rat & dog.

1.5.1.1.4 Role of CSQ2 in Ca2+ homeostasis
CSQ2 is the most abundant Ca2+ binding protein in cardiac membrane, although
several Ca2+-binding proteins such as histidine-rich Ca2+ binding proteins and
sarcaluminin are also present in high levels in SR lumens [16]. From the time of its
discovery, CSQ was predicted to act as a Ca2+ buffer and storage protein [91]. Earlier
acute overexpression studies in cultured adult rat cardiomyocytes have supported this
hypothesis, since doubling the levels of CSQ2 in cultured cells produced enhanced Ca2+
transients [92], and increased SR Ca2+ content (load), determined as 10 mM caffeine
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releasable Ca2+.

This was the first study to offer physiological data that the Ca2+

released during muscle contraction emanates from CSQ2, as the luminal Ca2+ storage
protein.

Studies of CSQ2 in bilayer experiments have shown that CSQ2 led to

increased RyR2 open probability [28, 93]. Such data suggested that, independent of
any effects on SR Ca2+ buffering, CSQ2 could act directly on RyR2, and that Ca2+
release may be regulated by CSQ2.
1.5.1.1.5 Characteristics of CSQ2-DsRed
DsRed, a red fluorescent protein cloned from the Discosoma coral [94], is an
obligate tetramer in vitro [95, 96] and in living cells [96], confirmed by a variety of
techniques. A unique subcellular localization of the fluorescent fusion protein CSQ2DsRed [19] around the nucleus was observed following its overexpression in cultured
adult rat cardiomyocytes. The ability to distinguish the red fluorescent CSQ2 polymer
from the more mobile monomer was made possible by the immunoreactivity of
monomers, and loss of immunoreactivity in the CSQ2-DsRed polymer. The resultant
pattern showed that the CSQ2-DsRed polymer first accumulates in perinuclear rough
ER, and is only able to traffic anterogradely as a monomer (Figure 1-7).
Figure 1-7. CSQ2-DsRed in
adult cardiomyocytes. When
CSQ2 is fused to the fluorescent
protein
DsRed
it
forms
tetramers that fluoresce red.
These tetrameric CSQ2-DsRed
complexes are, interestingly,
non-immunoreactive with either
anti-CSQ or anti-DsRed (green).
(A) Within 20 h overexpression
of CSQ-DsRed adenovirus, anti-DsRed detects CSQ fusion protein around the nucleus
that slowly traffics peripherally. (B) By 48 h in culture, DsRed tetramers are fluorescing
around the nucleus as protein levels build up. Meanwhile, the monomeric CSQ2-DsRed
continues trafficking peripherally (Modified from [85].
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1.5.2 Triadin
TRD is a transmembrane protein of junctional SR that binds to CSQ and may
anchor CSQ to the RyR. It was first identified in 1991 as a 95 kDa integral membrane
protein enriched in junctional SR vesicles from skeletal muscle, but a smaller,
alternatively spliced form was reported in heart in 1996 [97]. The majority of the protein
sequence (C-terminus) is localized in the SR lumen, with a single membrane spanning
domain and a short N-terminal positively-charged cytoplasmic segment [81, 98] that
binds on one side of a “KEKE” motif within a beta sheet structure [99].
The primary isoform expressed in cardiac muscle is triadin-1 (TRD in this
manuscript), a shorter splice variant of skeletal muscle triadin, arising as an alternative
splicing from a common gene. For the first 257 amino acids, triadin in cardiac and
skeletal muscle are identical. However, cardiac muscle TRD incorporates a unique 21
amino acid cardiac specific tail [97, 99]. On SDS-PAGE, canine cardiac TRD appears
as a doublet, the glycosylated and unglycosylated forms resolving at 40 kDa and 35
kDa, respectively [99].

Mouse cardiac TRD also occurs in both glycosylated and

unglycosylated forms [100]. It has been shown in a non-muscle cell model that the
unglycosylated form of triadin is more rapidly being broken down by the proteasome
[101]. The glycosylation site (75Asn) is only 7 residues from the ER membrane surface,
which makes its glycosylation very inefficient. Why the TRD sequence has maintained
this inefficient level of glycosylation through its evolution remains an enigmatic feature
of its structure and cellular processing.
1.5.3 Junctin
In 1995, JCT was purified and its primary structure determined; it exhibits
significant sequence identity to the liver ER aspartyl β-hydroxylase, representing a
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unique splice variant present in striated muscle cells. It has limited homology with rabbit
skeletal muscle TRD, especially in the transmembrane region (type II signal anchor
domain).

JCT is enriched in junctional SR membranes from skeletal and cardiac

muscle [102]. JCT consists of 210 amino acids with a molecular mass of 26 kDa; it has
a short amino acid cytoplasmic N-terminus, a single transmembrane domain and a
highly charged C-terminal luminal tail that can bind CSQ2 [103]. The protein in heart
does not from disulphide-linked oligomers and does not appear to be glycosylated [103].
1.5.4 Junctional sarcoplasmic reticulum protein-protein interactions
TRD has been shown to bind CSQ [104], RyR [81] and interact with JCT [27]
through a common luminal domain. The binding sites for CSQ [104] and RyR [105]
contain a KEKE motif localized within residues 210-224. Since electron microscopy of
intact muscle shows CSQ adherent to the luminal face of the RyR [106] and TRD has
the ability to bind both RyR and CSQ, it can be inferred an anchoring function for TRD
of CSQ.
Immunofluorescence and immunoblotting show that JCT co-localizes with CSQ
and RyR [103]. In junctional SR vesicles, JCT has been shown to be the major CSQ
binding protein in SR [102]. The high levels of basic amino acids were predicted to be
important for JCT’s ability to bind to CSQ to provide a membrane anchor for CSQ [73].
The CSQ binding domain on JCT was localized by fusion protein analysis to the
intraluminal region amino acid residues 46-210, the region containing the charged
amino acids [27]. In the same study, JCT was shown to interact with CSQ, and the RyR
in a Ca2+ dependent manner and with TRD in a Ca2+ independent manner. Other
studies have more recently suggested that JCT and TRD are not simply redundant, but
might have distinct properties and detailed functions in the myocyte [83].
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1.6 Hypertrophy
When heart muscle get progressively weaker and can no longer pump enough
blood to meet the metabolic needs of the body, heart failure (HF) can develop from such
ventricular dysfunction. Heart failure may also result from one or the sum of many
causes. Such a progressive disorder must be managed in regard to not only the state
of the heart, but to the condition of the circulation, lungs, neuroendocrine system and
other organs as well.
Associated with ventricular dysfunction are alterations in cardiac size, shape and
function.

These changes can result from changes in specific genomic expression,

molecular mechanisms, or subcellular structures. Recent studies have observed that Ttubule integrity is lost in a mouse model of ventricular hypertrophy and HF [107]. The
reasons for T-tubule reorganization are under active investigation. One current focus of
study is the junctional SR protein junctophilin-2, a transmembrane protein that is able to
interact with phosphoinositides in the T-tubules.
As a direct activator of myofilaments and thus contraction, Ca2+ is fundamental
for heart function. In the failing heart, there can exist an inability to properly regulate the
Ca2+ transient or Ca2+ interaction with contractile proteins. Changes in the steady-state
distribution of Ca2+ within the cardiomyocyte of stressed and failing hearts are thought
to underlie reduced contractility [108-110].

Candidate mechanisms for reduced

contractility include changes that prevent normal filling of SR Ca2+ stores, normal
release of Ca2+ [109, 110], and Ca2+-dependent changes in transcription [111-115].
We recently showed that CSQ2-DsRed protein accumulation at juxtanuclear sites
could strongly stimulate local spontaneous release of Ca2+ through RyR [116, 117].
This compartment is also the putative site at which CSQ2 is co-translationally
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phosphorylated by protein kinase CK2 [66]. Concentration of CSQ2 in this juxtanuclear
subcompartment might contribute to a functional Ca2+ microdomain that supports a
cardiac remodelling phenotype [108, 113].
1.6.1 Cardiomyopathies linked to genetic changes in protein components of the
Ca2+-release complex in mice
Mouse models of the protein components of the Ca2+-release complex, while
validating possible roles of CSQ2 in Ca2+ release, have not been successful in resolving
molecular mechanisms of Ca2+ release or junctional SR formation.

Beyond the

complexities that underlie the likely molecular mechanisms, mouse genetic models have
ended up leading to changes in multiple protein components (Table 1-2).
Mechanical stress, humoral factors or altered cardiac gene expression lead to
cardiac hypertrophy, a fundamental adaptation of the adult heart [118]. The central role
of Ca2+ signaling in cardiac hypertrophy is apparent from studies on transgenic mice in
which the overexpression of genes encoding for components of this pathway, such as
the L-type Ca2+ channel, calcineurin and NFAT, TRD, JCT, CSQ2 and Gqα, all result in
hypertrophy [119].
Transgenic mice that overexpress CSQ2 have a particularly marked phenotype
that is characterized by severe cardiac hypertrophy and decreased depolarizationinduced Ca2+ release from the SR. The overexpression of CSQ resulted in a
compensatory decrease in the expression of its binding partners (JCT, TRD and RyR2)
within the RyR2 complex [106, 120]. The increase in transcription during hypertrophy
might result from subtle alterations in the spatio-temporal properties of the individual
Ca2+ spikes. Indeed, a broadening of the Ca2+ transient or an increase in its amplitude
have been recorded in cases in which hypertrophy is induced by modifying the levels of
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proteins associated with RyR2 [119].
Table 1-2. Summary of junctional SR protein overexpression and suppression studies
Gene
Symbol

TRDN

Name

Overexpression
/Suppression

Animal
Model

Effect on Other Proteins

Implications

Triadin

Null

Mouse

Downregulation of
junctophilin-1 and -2

---

[129]

Mouse

Reduced expression of JCT
and RyR

Hypertrophy,
impaired relaxation
and reduced
contractility

[130]

Mouse

No changes in SERCA2a,
CSQ, PLB and PMCA
ATPase levels. RyR
expression levels
decreased 28%, however
the phosphorylation of
S2809
RyR was increased by
57%

Mild cardiac
hypertrophy,
prolonged
relaxation, a
blunted response to
β-adrenergic

[131]

Mouse

Reduced expression of
RyR2 (50%), CSQ2
(~60%), JCT (~92%) and
junctophilin-1 and -2
(~40%). No significant
changes in the nonjunctional SR proteins:
SERCA2a, PLB

Loss of Ca2+
release units,
impaired E-C
coupling, and
cardiac arrhythmias

[132]

Overexpression

Cooverexpression
of canine TRD
and canine JCT

Null

JCTN

CASQ

Junctin

Calseq
uestrin

Abnormalities in
muscle contraction,
narrowing of
junctional SR,
compaction of CSQ
and excess Ttubule SR
interactions
Increased
susceptibility to
atrial fibrillation
Enhanced cardiac
function in vivo,
JCT deficient
cardiomyocytes
exhibited increased
contractile and
Ca2+ cycling
parameters

Ref.

[133]

Overexpression

Mouse

---

Overexpression

Mouse

---

Null

Mouse

No significant changes in
RyR, phosphorylation of
S2809
RyR, TRD or CSQ,
2+
histidine-rich Ca -binding
protein, FKBP12.6, SERCA
or phospholamban levels

Murine CSQ
overexpression

Mouse

No downregulation of RyR,
TRD or JCT

Hypertrophy and
impaired Ca2+ induced Ca2+ release

[136]

Reduced expression of
RyR, TRD and JCT

Impairment in Ca2+
2+
-induced Ca release and
decreased Ca2+
spark frequency,
severe hypertrophy
and heart failure

[106,
137]

Canine CSQ2
overexpression

Mouse

[134]

[135]
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Ablation of the CASQ2 gene in mice (CASQ-/-) produces a cardiomyocyte
phenotype in which the SR Ca2+ release is not significantly different from that of wildtype myocytes. A 50% increase in total SR volume in these mice could contribute to the
lack of change in the free Ca2+ concentration. Another possible explanation would be
that an increase in other SR Ca2+ binding proteins has occurred in response to the loss
of the Casq2 gene [121]. Subsequent studies of a heterozygote (CASQ+/-) mouse
models exhibited 25% reduction in CSQ2 levels with no effects on other junctional SR
proteins.

The CASQ+/- model showed spontaneous SR Ca2+ releases, due to an

increase in diastolic SR Ca2+ leak that was similar to changes seen in some CPVT
models [122] that is; dysregulation of Ca2+ release.
Thus, mice with chronic changes in CSQ2 appear to develop general
malformation of Ca2+-release complexes. Functional changes reported in these mice,
however, may not be useful models for deciphering the functions of cardiac CSQ2.
Nevertheless, studies of heterozygote mice (CASQ2+/-) that exhibited roughly 25%
reductions in CSQ2 levels may be useful since the generation of a so-called “diastolic
leak” supports a function for CSQ2 in regulating the closing of the RyR2 channel. A
significant number of point mutations in human CASQ2 are also associated with a
recessive form of CPVT [123, 124], and studies have suggested similar clinical
phenotypes for RyR2- and CSQ2-induced diseases [125]. Moreover, partial knockdown
of CSQ2 [122] also leads to a phenotype similar to CPVT, supporting a major role for
CSQ2 in regulation of RyR. In depth studies of the first reported mutation in CSQ2
(D307H) showed that the mutant protein was not capable of undergoing the appropriate
conformational changes for the Ca2+ concentrations expected to occur inside junctional
SR lumens, nor was it capable of binding efficiently to its target proteins JCT and
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TRD[126].
1.7 Cytoskeleton
1.7.1 Cardiac cytoskeletal components
The integrity of cardiomyocytes is maintained by the cytoskeleton, which is
divided morphologically into nuclear, membrane-submembrane, sarcomeric and extrasarcomeric [127]. The nucleus is supported by a nuclear lamina, located below the
inner nuclear membrane and consisting of a dense network of intermediate filaments,
lamins, and interacts with both chromatin and the nuclear envelope.

This whole

complex is connected to the extra-sarcomeric cytoskeleton, actin, and T-tubules [128].
The membrane-submembrane cytoskeleton serves as the connection between
sarcomeres and sarcolemma, and consists of the focal adhesion proteins (vinculin, talin
and integrin), spectrins (spectrins, ankyrin and 4.1 proteins) and the dystrophindystroglycan complexes [138].
The sarcomeric cytoskeleton consists of thin filaments (cardiac beta- and
gamma-actin, C- I- and T-troponins and alpha-tropomyosin), thick-filaments (myosin
and myosin binding proteins C, H and X) and the Z-disk.

The sarcomere, extra-

sarcomeric cytoskeleton and the sarcolemma meet at the Z-disk. The extra-sarcomeric
cytoskeleton is composed MTs, intermediate desmin filaments and actin microfilaments
[138].
1.7.2 Microtubules and endoplasmic reticulum
Electron microscopy shows a close relationship between ER tubules and MTs,
where they are closely parallel over considerable distances [139, 140]. Furthermore,
evidence from studies utilizing live cell imaging show that MTs drive ER tubule
extension.

Tubule extension is mechanistically achieved in three distinct ways:
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association between ER and the (+) end of MTs through tip attachment complexes
(TAC), sliding of ER membrane on MTs that move through the cell as an intact entity,
and a more predominant and faster motor driven movement [141-143].
In vitro formation of ER tubules and network can be generated without the
cytoskeleton [144], thus, MTs are essential more in ER tubule extension and movement
than formation [145].

In vivo, stable interactions between MTs and ER associated

proteins are important for the ER network [146].
1.7.2.1 Microtubules
MTs are hollow cylindrical structures (diameter 24 nm), built from 13 parallel
protofilaments. They are composed of repeated heterodimers of 55 kDa α- and βtubulin globular proteins. α- and β-tubulin molecules are homologous but not identical,
each comprises several isoforms and, thus can have distinct locations in the cell, and
perform different functions [127].

MTs are dynamic where they undergo phases of

growing and shrinking. The binding and hydrolysis of GTP by tubulin subunits is known
to lead to dynamic instability of the MTs [147].
MTs form a network that spans transversely and longitudinally along the
cardiomyocyte axis and densely around and between nuclei [140, 148]. More generally,
MTs play a role in maintaining cell integrity [149] and are involved in organelle transport
[150], protein synthesis, and intracellular transport [151, 152]. Studies on membrane
ion channels in cardiomyocytes support the role of MTs in ion channel delivery [153,
154].
1.7.2.1.1 Microtubule disrupting agents
MT depolymerizing agents cause a drastic alteration in the morphology of the
ER.

Studies have demonstrated that many intracellular events rely on proper ER
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network morphology. Mutations in proteins that localize to ER, identified in a class of
neurological disorders underscore the medical importance of understanding intracellular
membrane protein trafficking and localization that allow the ER to serve its
multifunctional roles.
Nocodazole (methyl [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]) is a synthetic
compound that depolymerizes MTs and inhibits tubulin self-assembly [155].
Nocodazole acts through inhibition of polymerization of tubulin subunits, leading to depolymerization of dynamic microtubules [156, 157]. ER network collapse towards the
center of the cell and the formation of sheet-like structures has been demonstrated
upon nocodazole depolymerization of the MTs [158, 159].
1.8 Adenovirus mediated overexpression in cardiomyocytes
Several key characteristics of neonatal and fetal cardiac myocytes such as the
dynamic culturing nature, expression of signaling molecules, transcription factors, Ca2+
handling protein isoforms and morphological and sarcomeric organization have made
difficult the extrapolation of data to adult cardiac myocytes [160-162]. Therefore, in vitro
gene transfer through viral vectors to isolated adult cardiomyocytes is a powerful
experimental approach in understanding structure and function.
Adenovirus is a member of the Adenoviridae class of viruses. The Ad vectors
are one of the most efficient methods for in vivo and in vitro transduction. The most
commonly used biomedical reagents are engineered replication-deficient serotypes Ad
2 and 5, where CMV promoter drives foreign gene expression. The adenovirus virion
consists of a proteinacous capsid that surrounds the double-stranded DNA, and vertices
that serve to attach the virus to the host cell membrane containing coxsackievirus
(CAR) or adenovirus receptors [163]. Once the Ad is endocytosed, the double stranded
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DNA migrates to the nucleus and is transcribed [164].
In the studies described in Chapter 4 and 5, expression of canine junctional SR
proteins was performed at comparable levels to endogenous proteins in cultured adult
rat cardiomyocytes using Ad vectors, driven by CMV promoter.
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CHAPTER 2
MATERIALS AND METHODS
2.1 Animals and heart tissue
The investigation conforms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publication No. 85-23,
revised 1996). The studies performed using Sprague-Dawley (Rattus norvegicus) rats
(Harlan Laboratories, IN) were approved by the Wayne State University Animal
Investigation Committee (Appendix B).
Heart tissue was obtained from sham-treated control dogs (C) and dogs in heart
failure (HF) as frozen samples saved in liquid N2. Ischemia-induced HF (HFi) was
induced by multiple sequential intracoronary embolization’s with microspheres
performed in mongrel dogs 1-3 weeks apart over 6 months, and was discontinued when
left ventricular (LV) ejection fraction was ≤35%, as previously described [165], and
animals were sacrificed after 3 additional weeks. Samples of the posterior wall from the
LV were stored at -80 oC, and thawed prior to tissue homogenization. For tachypacinginduced HF (HFt), LV dysfunction was induced by rapid ventricular pacing in mongrel
dogs at >180 beats/min for >4 weeks to produce HF (ejection fraction ≤ 35%), and
animals were generally sacrificed within 1-3 weeks [166]. Samples of LV posterior wall
and septum were removed, and stored in liquid N2. Samples of frozen tissue used in
the present studies were thawed prior to tissue homogenization.
2.2 Purification of CSQ2
CSQ2 was purified from frozen tissue samples (2-5 g) as previously described
[167, 168].

Briefly, heart tissue samples were homogenized using Polytron

homogenizer (PT 10-35) at speed 5 for 30 sec in a Buffer A pH 8.0 containing 15 mM
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Tris Base, 200 mM NaCl, 0.5 mM EGTA and a phosphatase inhibitors mixture of 5 mM
NaF, 5 mM Glycerol 2-phosphate Disodium salt Hydrate and 5 mM NaPPi, were added
to the homogenate.

Triton X-100 was then added to the homogenate at 1%.

Homogenates were then transferred to centrifuge tubes and centrifuged using Sorvall
RC 5B PLUS (SS-34 rotor) at 35,000 x g for 45 min after which supernatants were
collected.
The

collected

supernatant

was

then

applied

to

an

anion

exchange

chromatography column of DEAE-sephacel (Diethylaminoethyl Sephacel© (Sigma
I6505).

The column was then washed with several volumes of Buffer A pH 8.0

containing 220 mM NaCl and 0.5% Triton X-100 then followed by Buffer A pH 8.0
containing 220 mM NaCl. A salt dependent elution was then performed with Buffer A
pH 8.0 containing 700 mM NaCl (Buffer B).
The collected elutions were then applied to a column of phenyl-Sepharose CL-4B
(Sigma P7892) equilibrated with Buffer B pH 8.0. The column was then washed with
several volumes of Buffer B to remove contaminants. A Ca2+ dependent elution was
then performed using Buffer B with 20 mM CaCl2. Spectrophotometry was performed at
280 nm on the collected elution fractions. The protein samples were then desalted by
repeated washes with HPLC grade water (Fisher Scientific) through centrifugal filters
(Amicon® Ultra-0.5 ml 10K, Millipore UFC501096). Concentrated fractions (1 g) was
run on acrylamide gel and visualized using Coomassie® Blue stain on gel (section
2.5.2).
2.3 Cardiomyocyte isolation
2.3.1 Surgery
Hearts were obtained from male Sprague Dawley rats weighing between 175-
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200 g. Following standard protocol the animals were anesthetized with 300 mg/kg
bodyweight by peritoneal injection of 5% Avertin (tribromoethanol) working solution in
PBS (Sigma, P4417). The working solution was prepared from a 50% stock of 2,2,2tribromoethanol (Sigma T48402) dissolved in 2-methyl-2-2butanol (Sigma 240486).
The incision area was sterilized using 70% ethanol. The chest was opened and the
heart was excised with a large portion of the aorta intact and placed immediately in cold
solution A (described In section 2.3.2).
2.3.2 Isolation protocol
Cardiomyocytes were isolated by retrograde perfusion using the Langendorff
apparatus [169]. Briefly, the heart was hung with the aorta clamped and tied with a
suture to a 1.8 mm aorta cannula (Radnoti 140153-16), to ensure good perfusion the
aorta was not pushed too far into the heart. Perfusion with warmed/oxygenated Ca2+free solution A containing 10.0 mM HEPES (Sigma H-4034), 1.2 mM KH2PO4, 5.0 mM
Pyruvic acid (Sigma P5280), 110.0 mM NaCl (Sigma S6191), 1.2 mM MgSO4 (Sigma
M2643), 5.0 mM creatine (Sigma C3630), 4.8 mM KCl (Sigma P5405), 11.0 mM
Glucose (Sigma G7528) and 5.0 mM taurine (Sigma T8691) was carried out for 5 min.
to wash out the heart. Enzymatic dissociation was then carried out using solution A with
5 mg Liberase TM Research Grade (Roche 05401127001) and 0.1 mM CaCl2 (Sigma
C7902).

After 15-20 min of enzymatic digestion, the ventricles were cut from the

cannula and placed in a dish along with the enzyme containing solution A in a 37 oC
water bath for 10 min for further enzymatic digestion. The mixture was then filtered
through nylon mesh into a 50 ml Falcon conical tube. The filtrate was spun in swinging
bucket centrifuge for 2 - 5 min at ~1200 rpm until a light pellet formed. The cell pellet
was resuspended with solution A containing 250 μM CaCl2, centrifuged for 2 - 5 min at
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~1200 rpm until a light pellet formed, supernatant was discarded and cell pellet was
resuspended with 500 μM CaCl2 centrifuged for 2 - 5 min at ~1200 rpm until a light
pellet formed, supernatant was discarded and cell pellet was resuspended as described
below (section 2.3.3).
2.3.3 Cardiomyocyte culture
Cells were resuspended in Medium 199 (Invitrogen 12340-030) containing 2%
bovine serum albumin (Sigma A1933), 2 mM carnitine (Sigma C0283), 5 mM creatine
(Sigma C3630), 5 mM taurine (Sigma T8691), 2 mM L-glutamine, 2 mM Glutamax-1
(Invitrogen 35050-061), 25 M blebbistatin (Toronto Research Chemicals B592500), 1%
Penicillin-Streptomycin (Invitrogen 15070-063), 1% ITS (Sigma I3146), 2 mM Lglutamine (Sigma G7513), 1% MEM non-essential amino acids (Invitrogen 11140-050).
The cells were examined under the microscope (Nikon Eclipse TS100) and then stained
with trypan blue (0.4%) (Sigma T8154) and counted using hemacytometer (Reichert) for
plating. The isolated cardiomyocytes were plated in 6-well dishes (50,000 cells/well)
containing coverslips coated with laminin (Sigma L2020) at 37 °C with 5% CO2 and
cultured up to 48 h.
2.4 Cell treatments
2.4.1 Adenovirus infection
Adenoviral CSQ2-DsRed (Ad.CSQ2-DsRed), CSQ2 (Ad.CSQ2), TRD (Ad.TRD)
and JCT (Ad.JCT) vectors were previously described [84, 170, 171]. To determine the
virus concentration (plaque forming units, pfu/l), HEK 293 cells (ATCC) were plated at
0.2 x 106 cells/well and the viruses were added the next day as follows: 10, 3, 1, 0.3,
0.1, 0.03, and 0 µl. For the purposes of estimating a concentration we assumed that
100% decimation of the cells was a multiplicity of infection (MOI) of 1. This assumption
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was frequently checked by commercial assays. Calculation of pfu/cell was determined
based on viable rod shaped cardiomyocytes not total cell count.
As previously described [19], adenoviruses were added directly to dishes 2 h
post-plating at MOI=200 (1x). In Chapter 5, the cardiomyocytes were infected with up to
5x Ad.CSQ2 in order to visualize the initial sites of accumulation following its protein
synthesis. For all adenoviral studies, treatments were carried out for 12 or 16, 24, 30
and 48 h as indicated before harvesting for biochemical analysis and fixing of coverslips
for microscopy.
2.4.2 Nocodazole treatment
Nocodazole (Sigma M1404) (20 M) was diluted in Medium 199 and added to
cardiomyocytes 16 h post-plating. Cardiomyocytes treated (+) with nocodazole up till 32
h in culture where as cells cultured under similar conditions without nocodazole (-),
served as control.
culture.

Cells were fixed for immunofluorescence studies after 48 h in

Treatments with nocodazole for last 2 h prior to harvesting and fixation,

however, did not show any marked disruption. Therefore, we opted to add nocodazole
12-16 h post-plating (Appendix C Figure A-3).
2.5 Electrophoresis
2.5.1 Protein extraction and concentration determination
Protein extraction from cultured cardiomyocytes was performed as follows,
immediately after removal of coverslips for immunofluorescence analysis (see section
2.6.3.1), 6-well dishes were placed on ice and cells were scrapped and transferred with
media into 15 ml Falcon conical tubes.

The cells were centrifuged using ADAMS

DYNAC centrifuge (Clay Adams Inc.) for 10 min at 4 oC and media was discarded. The
cell pellet was resuspended with PBS and centrifuged at the same settings.
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Supernatant was again discarded and cell pellets were resuspended with 200 µl
extraction buffer (10 mM Tris, 200 mM NaCl, 1% triton X-100, 0.5 mM EGTA, pH 8.0),
centrifuged after which protein extracts were collected and saved in -80 oC for later
determination of protein concentration by Lowry assay [172] and electrophoretic
analysis.
2.5.2 Gel electrophoresis
SDS-PAGE was carried out according to Laemmli [173] on 7% or 10%
acrylamide gels using Hoefer® GE600 Chrome apparatus (Amersham) or on 10% BisTris MIDI gels (Invitrogen) according to manufacturer. Gels were transferred to
nitrocellulose membranes (0.45 m, BioRad Laboratories) and stained with Amido Black
(Sigma).
2.5.3 Concanavalin A binding to glycoproteins
Similar amounts of purified CSQ2 from heart samples were analyzed by
immunoblotting based on immunoblot quantification.

Duplicate nitrocellulose strips

were then analyzed by immunoblotting (section 2.6.2) or Con A binding. For Con A
binding to CSQ2, one strip without prior non-specific protein blocking of membrane was
incubated in phosphate buffer saline with 0.2% tween20 (PBS/tween) containing Con A
conjugated to peroxidase (Sigma, L6397) at 10 μg/ ml for 90 min at room temperature
[174]. The strip was rinsed three times for 5 min each, and then developed using
enhanced chemiluminesence (ECL) reagents (Pierce 32106). ECL and quantitation of
digitized scans were performed to determine Con A binding/μg CSQ2 using ImageJ
(Wayne Rasband, National Institutes of Health).
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2.6 Immunological methods
2.6.1 Antibodies
Antibodies used in immunoblotting and immunofluorescence assays were as
follows: anti-CSQrat (Abcam ab3516), anti-CSQdog, anti-JCTdog and anti-JCTrat antibodies
were the generous gift of Dr. Larry Jones, Indiana University School of Medicine.
Monoclonal anti-CSQ2 antibodies used for assays in Chapter 2 are previously
described [85]. Anti-TRDdog antibodies were as previously described [175], anti-TRDrat
were purchased from Thermo (MA3-927). Tubulin antibodies were as follows: antialpha tubulin (Sigma T6074) and anti-beta tubulin (Sigma T5201). Alexa Fluor 488 or
568 conjugated goat anti-rabbit IgG, Alexa Fluor 488 or 568-conjugated goat antimouse IgG secondary antibodies were purchased from Invitrogen.

Relative

specificity/selectivity of the antibodies used towards dog or rat junctional SR proteins
indicated by (+) or (-) are shown in Table 2-1.
Table 2-1. Relative reactivity of junctional SR protein antibodies to dog or rat forms.
Species Reactivity
Protein Target

Antibody

Dog

Rat

anti-TRDdog

+

-

polyclonal

anti-TRDrat

-

+

monoclonal

anti-JCT dog

++

-

monoclonal

anti-JCT rat

+

++

polyclonal

anti-CSQdog

++

-

monoclonal

anti-CSQrat

+

++

polyclonal

TRD

JCT

CSQ

2.6.2 Immunoblot
Immunoblotting was carried out as previously described [176].

Briefly, the

nitrocellulose membranes were blocked with 1 mg/ml bovine serum albumin in
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PBS/tween for 15 min and then incubated with primary antibodies solution in PBS/tween
for 90 min and then washed three times with 15 min. Primary antibody dilutions were
adjusted to assure that ECL signals for multiple antigens on a single exposure of film
remained within a linear range. Membranes were then incubated in PBS/tween with
horseradish peroxidase-conjugated goat anti-rabbit IgG and goat anti-mouse IgG
secondary antibodies (1:30,000) (Jackson ImmunoResearch Laboratories) for 45 min
and then washed with PBS/tween.

ECL reagent was used to detect immune

complexes, which were then visualized by autoradiography using high resolution
Amersham Hyperfilm ECL film (GE Healthcare). Autoradiograms were quantified using
ImageJ.
2.6.3 Immunofluorescence
2.6.3.1 Immunocytochemistry on isolated cardiomyocytes
Briefly, cells grown on coverslips were fixed with 4% paraformaldehyde in PBS
for 15 min and then permeabilized for 10 min in 0.2% PBS/tween. Coverslips were
blocked in PBS with 0.2% Tween-20 (PBS/Tween) and 2% goat serum at room
temperature for 20 min. Cells were then incubated in PBS/Tween with primary antibody
(1:100) overnight at 4°C, followed by washing in PBS/Tween, and incubation with goat
anti-rabbit IgG or goat anti-mouse IgG antibodies conjugated to Alexa Fluor dyes (1:100
dilution in PBS/Tween for 120 min). Cells were counterstained with NucBlue Fixed Cell
ReadyProbes Reagent (Molecular probes R37606) for 30 min. rinsed, and mounted to
microscope slides with ProLong Antifade Mounting Kit (Molecular Probes).
2.6.3.2 Immunohistochemistry on tissue sections
Frozen LV tissue from C and HF hearts were removed from liquid N2 and
embedded in OCT compound, sliced by cryostat (-21 °C, 10 m thickness), and dried
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on Superfrost® Plus Gold slides (Fisherbrand). The slices were hydrated in PBS and
the OCT washed three times in PBS at RT.

Fixation was performed with 4%

paraformaldehyde in PBS for 15 min, and washed three times, then blocked with 1%
goat serum in PBS-tween for 4 h; all carried out at ambient temperatures. Antibodies
were premixed before use to attain uniform distributions. The primary antibody mixture
contained 1:50 dilutions of mouse anti-CSQ2 monoclonal (mAb) 4E7 and rabbit antiCSQ2 polyclonal (pAb), and was applied for 24 h at 4 °C. Equal volumes of the two
antibodies contained roughly equivalent ECL signals against purified canine CSQ2
using the same respective anti-IgG goat antibodies used for immunoblotting. Slides
were than washed three times for 5 min. The secondary antibody mixture contained
1:200 dilutions of goat anti-mouse Alexa Fluor 488 (Invitrogen) and goat anti-rabbit
Alexa Fluor 568, and was applied 4h at RT. Slides were then washed three times for 15
min in PBS/tween, RT, stained with 100 µM 4′-6-diamidino-2-phenylindole (DAPI) for 2
min, and washed for 10 min in PBS/tween, RT. Coverslips were mounted for imaging
using a drop of ProLong Gold Antifade (Invitrogen).
2.7 Fluorescence microscopy
Imaging of tissue and cardiomyocytes was performed using a 63 ×/1.4 oil
objective on a Leica DMI 6000B system. All confocal images were acquired at the
same settings and were concurrently processed and optimized offline for publication
using Photoshop (Adobe Systems Inc.).

Fluorescence intensity quantification was

performed using ImageJ (Wayne Rasband, National Institutes of Health).
Transverse lines of 50 pixels were used to select areas that extended from the
cell edges and included the center of one nucleus (in tissue staining) and to the edge of
the nucleus (in cell immunostaining). The intensity of each color channel was plotted
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(red: pAB-CSQ-2, green: mAB-CSQ-2, blue: DAPI) in consecutive 3-μm steps distance
from the nucleus.

Values are plotted as fractional deviations from the average

fluorescence intensities for each channel.

Channel values were standardized for

plotting using Microsoft Excel.
2.8 Quantitative PCR
RNA extraction from heart samples was performed using RNeasy Fibrous tissue
Mini Kit (Qiagen). One microgram of DNase-treated total RNA sample was reverse
transcribed by reverse transcription (Applied Biosystems). Quantitative PCR with fast
SYBR green (Applied Biosystems Step One with v2.0 software) was performed using
canine specific primers designed to span one intron. Canine primers were as follows:
GAPDH: forward, CCCCTTCATTGATCTCAACTACATGGT
reverse, CCCGTTGATGACAAGTTTCCCGTTC-TC
CSQ2: forward, CCAAGCTTGCCAAGAA-GCTGGGT
reverse, ACGTCAGCTGCAAACT-CGCCA
ANF: forward, AGAGCGGACTGGGC-TGCAACA
reverse, CCCAAGGGACGAGGGT-CTCTCA
BNP: forward, ACTACGCAGCCCC-AAGATG
reverse, CCTCAGCACTTTGCAGC-CCA

Relative quantitation method (∆Ct) was used to evaluate mRNA levels for CSQ2,
along with hypertrophic markers atrial natriuretic factor (ANF) and brain natriuretic
peptide (BNP).

Fold change (2-ΔCt) relative to glyceraldehyde 3-phosphate

dehydrogenase (GAPDH) mRNA levels was used. GAPDH mRNA levels were highly
similar between C and HF samples.
2.9 Mass spectrometry
In order to measure the mass to charge ratio (m/z) mass spectrometry was used.
Small highly charged droplets are formed by electrostatic dispersion of protein solution
through a glass capillary subjected to a high electric field. In order to calculate the
molecular weight of a particular peptide, the observed m/z ratio has to be corrected for
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(multiplied by) the number of attached protons [177]. Electro spray ionization mass
spectrometry of purified CSQ2 (ESMS) was performed at the Keck Biotechnology
Laboratories, Yale University, New Haven, CN using a Q-ToF mass spectrometer
(Micromass, Altrincham, UK), as previously described [167].

Protein samples were

resuspended or diluted in 20% acetonitrile, 0.1% formic acid.

The proteins were

trapped on a Michrom (Auburn, CA) protein cap trap using a Waters (Milford, MA)
CapLC. Trapped proteins were eluted into a Waters Q-Tof Ultima mass spectrometer
and their masses deconvoluted using the MaxEnt1 algorithm.
2.10 Statistical analysis
Data are presented as mean ± SEM. To determine differences between C and
HF groups, Student’s t-tests were performed, and P<0.05 was considered statistically
significant. Microscopy data for tissue slices from two hearts as mean ± SD.
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CHAPTER 3
ALTERED CALSEQUESTRIN GLYCAN PROCESSING IS COMMON TO DIVERSE
MODELS OF CANINE HEART FAILURE
3.1 Rationale
The N-linked glycan in CSQ2 from mammalian heart tissue normally undergoes a
high degree of trimming by intracellular mannosidases.

Minor differences in CSQ2

glycan structures have been previously noted in larger mongrel dog hearts [167]
compared to that of purebred beagles [178]. Interestingly, in beagles, CSQ2 glycans
exhibit a dramatic reduction in mannose trimming following a 6-8 week period of
tachypacing that produces HF [178]. To determine whether this is an effect specific to
the smaller animal or to a single type of cardiac stress, we broadened such
investigations to include two diverse experimental models of HF in the mongrel dog.
We report here that whether dogs receive ventricular tachypacing or are placed into
failure by ischemia due to recurring coronary microembolizations, dramatic and
qualitatively similar alterations of CSQ2 processing occur wherein normal CSQ2 is
replaced in HF tissue with protein that has not undergone the same degree of
posttranslational processing.
Hypothesis: CSQ2 trafficking within the cardiomyocytes is dramatically altered in
mongrel canine populations using two of the leading models of heart failure induction
3.2 Results
3.2.1 Analysis of CSQ2 glycoforms and phosphoforms
Purified CSQ2 analyzed using ESMS resolves CSQ2 into its polymorphic
spectrum of masses and provides quantification of individual CSQ2 molecular
structures. Detailed knowledge regarding mannose trimming of its

316

Asn-linked glycan
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can be deciphered from these mass spectra, which undergo loss of mass in 162 Da
steps that are indicative of mannose trimming [167]. Superimposed upon the mass
change for each glycoform can be additional mass changes due to changes in CSQ2
phosphorylation on its C-terminus (378,382,386Ser). The exact state of phosphorylation for
a given glycoform is obscured by the coincidental overlap in mass changes resulting
from mannose trimming (Δmass = 162 Da) and that resulting from differences from two
phosphates (2 x 81 Da = 162 Da) [167, 179]. Nonetheless, relatively large and very
consistent differences in CSQ2 mass peaks were found between control and failed
heart tissue samples occurring in steps of 162 Da and 81 Da that reflect differences in
steady-state levels of these two ongoing posttranslational processes.
Purified CSQ2 from C mongrel dogs exhibited a range of molecular masses,
having a weighted average of 46,306 Da, a value that is 1037  41 greater than its
deduced molecular weight of 42,269 (Table 3-1). CSQ2 masses, 90% of which were
between 46,001 and 46,487 Da, corresponded to CSQ2 molecules having glycans that
have

undergone

processing

by

intracellular

mannosidase(s)

to

structures

GlcNAc2Man3-5 (Figures 3-1 & 3-2). In contrast to the single uniform peak of CSQ2
masses present in C hearts, every heart from HF dogs contained CSQ2 molecules that
were less processed, and so were of greater mass. More striking was the appearance
of two broad groupings of mass peaks, demarcated Pool I and II (Figure 3-1).

A

prominent lower mass pool in HFt and HFi (Pool I) was relatively close in mass to the
single pool of CSQ2 found in C hearts, yet larger by 274  94 and 326  85 Da,
respectively (Table 3-I). The highly processed CSQ2 molecules found in all canine
hearts reflects the successive removal of mannose in more distal subcellular
compartments, processed by mannosidase(s) beyond that of the early ER [167].
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Although not structurally identical in C, HFi, and HFt hearts, it is hypothesized that this
larger pool of highly processed protein in each heart corresponds to junctional SR
CSQ2.
Table 3-1. Molecular masses (weighted averages ± S.D.) of CSQ2 from canine heart
tissue samples (Da)
Control

HF (Tachypacing)

HF (Ischemic)

Pool I (Man1-Man7 glycoforms)

100

Pool II (Man8,Man9 glycoforms)

0

68  20
32

68  9
32

Relative protein amounts

Weighted mass averages
All forms

46,306  41

46,811  116

46,798  196

Pool I (Man1-Man7 glycoforms)
Pool I (Increase from Control)

46,306  41
N/A

46,633  85
∆AVG = 274  94

46,581  94
∆AVG = 326  85

Pool II (Man8,Man9 glycoforms)

N/A

47,290  88

47,193  30

The second broad grouping of mass peaks (Pool II, Figure 3-1 and Table 3-I)
was comprised of protein that underwent either no mannose trimming, or removal of a
single mannose. This pool of CSQ2 is likely only acted upon by the well-characterized
ER α-1,2 mannosidase, characteristic of early ER, and known to produce Man8 from
Man9 [180, 181]. This is the mannose trimming typical of CSQ2 expressed in every
non-muscle cell examined to date [182]. This higher-mass pool of CSQ2 molecules
was only present in HF tissue, entirely absent form C mongrel dog heart tissue.
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Figure 3-1. CSQ2 masses are altered in heart tissue from mongrel dogs in heart failure.
a) CSQ2 was purified from control (C) canine heart, and hearts induced into failure by
repeated microembolisms over 6-9 months (HFi) or by tachypacing (HFt) for 4-8 weeks.
CSQ2 was purified from frozen tissue samples and intact CSQ2 was analyzed by
ESMS. Differences in CSQ2 mass isoform peaks correspond to the successive loss of
mannose sugars (mannose trimming, ∆mass = 162 Da) from the CSQ2 glycan.
Superimposed on each glycoform are changes in mass brought about by varying
numbers (0-3) of phosphates on CK2-sensitive sits (∆mass = 81 Da). Masses and
mannose content are shown across the bottom and top, respectively. CSQ2 mass
peaks corresponding to Man9,8 glycoforms are shaded. b) Summary raw data for all 15
heart samples (12 dog hearts). Mass peaks corresponding to glycoforms and
phosphoforms are plotted as a percentage of the total (%CSQ2 molecules). Five C
hearts (green spectra), 3 HFi hearts (red spectra), 4 HFt hearts (blue, posterior wall,
lavender, septal wall). Shaded area designates rough ER with Man9,8 (Pool II), while
further mannose trimming is designated as junctional SR (and Pool I). The presumed
mass of CSQ2 following biosynthesis and folding (mass = 47,478 Da; Man9 with 3
phosphates) indicated by an asterisk (*).
Redistribution of CSQ2 molecules from C heart tissue into two mass pools of
Man1-7 (Pool I) and Man9,8 (Pool II), was further analyzed by calculating separate
Gaussian distributions based upon the averages calculated from the three cohorts of
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mongrel dogs (Figure 3-2 panel a). Here we compared the average molecular masses
for the two putative CSQ2 pools, along with their relative abundances (relative peak
heights), and their standard deviations (relative peak width). Results from the current
three cohorts of mongrel dog heart samples were also compared with C and HF cohorts
previously reported for beagles [178]. From these canine heart samples, a general
pattern emerges wherein CSQ2 from C heart tissue (Figure 3-2 panel a, green curves)
is consistently comprised of a more highly processed collection of molecules, whereas
HF tissue has degraded those molecules, and replaced them with less processed, or
post-translationally "younger", molecules that accumulate in two distinct states of
posttranslational processing (Figure 3-2 panel a, red curves).
Because mannose trimming occurs in successive steps, and reflects protein
biosynthesis, processing, and degradation, the percentage of total CSQ2 remaining at
each step provides a perspective of its overall turnover (Figure 3-2 panel c). In C dogs,
trimming of the first 4 mannoses was not accompanied by any retention, and so 100%
of CSQ2 molecules proceed to latter steps of mannose trimming. The first four steps of
processing correspond to cleavage of (1-2) linkages by an ER (1-2)-mannosidase
(Figure 3-2 panel b, green circles). CSQ2 accumulated in the form of molecules with
additional mannose trimming, with successively fewer molecules of CSQ2 trafficking
forward.

This analysis suggests that the actions of a second enzyme ((1-3)-

mannosidase) might therefore be associated with the subsequent loss of mannose,
leading to loss of CSQ2 from the cardiomyocyte. We cannot determine from the mass
spectrometric data whether all molecules eventually underwent trimming to Man 3 on
their path to degradation, or whether all molecules with glycans of Man5-3 were
degraded directly.
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Figure 3-2. Further evaluations of CSQ2 mass spectra data. For the analyses shown
here, the direction of CSQ2 posttranslational processing is reversed from Figure 3-1,
which reflected the orientation of mass spectrometric data. In panels a, b and d, CSQ2
processing occurs left to right a) Weighted averages of CSQ2 masses were calculated
individually for Man9,8 and Man1-7 to construct a model of CSQ2 glycoforms based
upon low or high levels of mannose trimming (cf. Table 3-1). Control mammalian hearts
(C) show one peak of highly mannose-trimmed molecules (green peaks). In failing
hearts (HFi and HFt), the green peak is no longer present, having apparently degraded.
In its place is found a distinct phenotype exhibiting two CSQ2 pools (red peaks),
consisting of a prominent pool (Pool II) of poorly processed (Man9,8) protein and a pool
of junctional SR CSQ2 (Pool I) with glycan processing closer to that of control hearts.
Similarly modeled are data previously reported in tachypacing of beagle hearts that led
to HF (Ctb/HFtb) [178]. CSQ2 expressed in non muscle cells [182] produces only ERtype (Man9,8) CSQ2 (bottom panel) b) Sample structures of CSQ2 protein molecules
(C-termini) corresponding to masses as indicated. After biogenesis in rough ER, the Nlinked glycan on 316Asn is -GlcNAc2Man9, whereas CK2-sensitive sites (378,382,386Ser)
are fully phosphorylated, since phosphorylation occurs in the cytoplasm during
translocation of the nascent polypeptide [183]. Moieties are GlcNAc (black boxes),
mannoses (blue and green circles) -1,2 linked mannoses (green circles), phosphates
(red circles). Mannoses and phosphates removed by mannosidases and phosphatases
are represented by lightened symbols.
3.2.2 Analysis of CSQ2 glycans by Con A binding
To provide a gel-based assay to corroborate the mass spectrometric analysis of
CSQ2 glycans, we measured Con A binding to purified CSQ2 on nitrocellulose
transfers. Con A is a lectin known to bind to high mannose forms of N-linked glycans
[174, 184]. CSQ2 from hearts of HFt dogs, but not HFi dogs, bound significantly higher
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levels of Con A than CSQ2 from C dogs, indicative of the accumulation of the
unprocessed protein (Figure 3-3 panels a, b). For tissue samples analyzed both by
ESMS and Con A binding, a non-linear correlation was found between the percent of
CSQ2 in Pool II (ER CSQ2) and Con A binding (Figure 3-3 panel c).

This likely

reflected increased levels of Man9 compared to Man8, but this distinction was difficult to
confirm by ESMS because of the overlap of mass peaks due to overlap of masses
resulting from loss of mannose (mass = 162 Da) and phosphate (mass = 81 Da) [185].

Figure 3-3. Con A binding to purified CSQ2 from C and HF tissue samples. a) Con A
binding to purified CSQ2 on nitrocellulose membranes. Measurements were carried out
in 3 independent determinations of the same sample, from 16 hearts, including samples
of HFt posterior wall and septum (LV regions). Averages for each animal cohort of C,
HFi, and HFt are mean  SEM.; significance (p < 0.05) is indicated by asterisk (*).
Values for LV regions are mean  SD. b) Sample autoradiograms of CSQ2 antibody
binding (upper band) and Con A binding (lower band) for C and HFt sample. Data
shown in panel a is Con A divided by CSQ2 antibody binding, normalized to the values
obtained for CSQ2 from HEK cells (cf. Figures. 3-1a, 3-2a). c) Comparison of
percentage of CSQ2 molecules in ER (Pool II glycans) plotted against Con A binding,
for samples in which both types of data were obtained.
3.2.3 Steady-state CSQ2 protein and mRNA levels
Total steady-state levels of CSQ2 protein were measured in tissue homogenates
from C, HFi, and HFt mongrel dogs. Decreased total levels of CSQ2 were found in both
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HF dogs compared to C (Figure 3-4 panels a, b) with mean levels of CSQ2 reduced in
HFi and HFt by 86% and 58%, respectively, although neither was statistically significant.
Data were also obtained for CSQ2 mRNA levels in HFi and HFt. Compared to C hearts;
mRNA in HFi and HFt was increased by 33% and 72%, respectively (Figure 3-4 panel
c). Only changes in CSQ2 mRNA levels in HFt dogs attained statistical significance
(p=0.04).

Figure 3-4. Steady-state levels of CSQ2 protein, mRNA, and protein to mRNA ratios in
canine hearts. Total numbers of dogs were: C, n=6; HFi, n=5; HFt, n=5. Samples from
each dog were measured a minimum of four times. a) Canine heart homogenates were
analyzed by immunoblotting (30 μg/lane). Representative immunoblot data: Amido
black-stained nitrocellulose (Protein Stain) and autoradiogram for α -actinin and CSQ for
C, HFi and HFt. Molecular weight markers (left margin) are in kDa. b) Summary data for
C, HFi and HFt dogs normalized to α-actinin as loading control. Values are from 3
measurements for 5 dogs (mean  SEM, p-values for t-test, significance < 0.05
indicated by asterisk (*)). c) Data for levels of mRNA for CSQ2, ANF, and BNP,
determined by quantitative PCR for C, HFi, and HFt dogs (mean  SEM, p values for ttest; significance < 0.05 indicated by asterisk (*)). Values on right correspond to ANF
and BNP mRNA levels. d) CSQ2 protein to mRNA ratios calculated for each dog, and
averaged for C, HFi, and HFt dogs (mean  SEM, p values for t-test; significance < 0.05
indicated by asterisk (*))
Transcript levels for ANF and BNP were also determined as a measure of
hypertrophy in C, HFi, and HFt groups. Mean values for these two markers were highly
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increased in both HFi (ANF, 16-fold; BNP, 51-fold) and HFt (ANF, 18-fold; BNP 96-fold)
tissues compared to C (Figure 3-4 panel c). The increase in dog HF samples, while
very large, did not attain statistical significance, as large variations in transcript levels
were measured for individual dogs.

Reasons for variability were not further

investigated.
Since protein levels showed a tendency to decrease, in spite of increased mRNA
levels, we determined protein levels per mRNA levels, averaged for each dog (Figure 34 panel d). For HFt dogs, this measure of protein/mRNA was reduced by 3.0-fold
(p=0.003), whereas a lesser but not significant reduction was found for HFi dogs
(p=0.08).
3.2.4 Immunohistochemical analysis of canine tissue
Given the roughly one-third of CSQ2 that accumulates in an unprocessed form in
cardiac HF tissue, we tested whether this separate mass pool of CSQ2 might be
apparent by immunohistofluorescence microscopy.

The rough ER responsible for

CSQ2 biosynthesis is thought to localize to membranes surrounding myonuclei, based
upon studies of CSQ2-DsRed overexpression in cultured adult rat cardiomyocytes[117].
To determine whether there was enhanced CSQ2 immunofluorescence relative
to myonuclei in HF compared to C tissue, we analyzed thin sections of heart from C
tissue and from two different HFt tissue samples.
exhibited high levels of ER-CSQ2 by ESMS.

HFt samples were chosen that
Quantitative analysis of confocal

immunofluorescence from C and HFt tissue, showed no significant differences in
relative CSQ2 levels across the cardiomyocyte (Figure 3-5).
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Figure 3-5. Detection of CSQ2 in
canine
tissue
slices
by
immunofluorescence, and CSQ2
antibody reactivity. Tissue sections
were
analyzed
by
immunofluorescence
using
a
mixture of polyclonal (poly, Red)
and monoclonal (mono, Green) antiCSQ2 antibodies, each diluted 1:50.
Images were obtained as a series of
optical slices (Z-stack), and single
confocal images were selected for
quantitation, as described in
Methods a) Bar graphs show
integrated
intensities
of
fluorescence signals across a
transverse width for 12 individual
cells from five separate Z-stacks
obtained for two different left
ventricle tissue slices. Values are
total fluorescent intensity over
background (lowest intensity per
channel), averaged for all 12 cells
(mean intensity in each 3-μm
window for red or green channel
SD). Scale bar, 3 μm. b) Relative
immunoreactivity
for
roughly
equivalent IgG concentrations of the
two antibodies. Lane 1, 1.0 μg
purified canine CSQ2 from HEK
cells, which contains ~1.5 mol
phosphate on C-terminal sites and a
glycan of structure -GlcNAcMan9,8
[167, 182]; lane 2, 1.0 μg purified of
CSQ2 phosphorylation-site negative
mutant Ser(378,382,386)Ala from
HEK cells [183]; lane 3, 1.0 μg purified CSQ2 from Control canine ventricular tissue,
which contains ~1.5 mol phosphate on C-terminal sites and an N-linked glycan of
structure –GlcNAcMan4-6 ([179] and Figure 4). c) Sample confocal fluorescence
images from C and HFt tissue slices. Scale bar 3 μm. Enlarged field (white inset)
showing minor differences in immunoreactive localization. Scale bar 1 μm.
Interestingly, our data also supported the idea that there is more than a single
homogeneous pool of CSQ2 within canine cardiomyocytes.

Commercial anti-CSQ

polyclonal antibodies produced the expected intense punctate immunofluorescence,
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whereas canine-CSQ2-selective monoclonal antibody produced a similar but clearly
distinct immunofluorescence (Figure 3-5 panel c).

These differences in apparent

subcellular localization were most likely due to differences in accessibility of the epitope
for the monoclonal antibody (264EFLEILKQV), not to selective posttranslational changes.
Immunoblot analyses of relative CSQ2 immunoreactivities for the two antibodies
showed that neither the polyclonal nor monoclonal antibodies exhibited differences in
CSQ2 immunoreactivity that stemmed from its level of endogenous phosphate or its
degree of glycan processing (Figure 3-5 panel b).

This was tested by comparing

reactivities against recombinant canine CSQ2 from HEK cells, in which little mannose
trimming occurs [186], or a phosphorylation-site mutant Ser(378,382,386)Ala [183], or
CSQ2 from C dog heart which contains phosphate and undergoes substantial mannose
trimming.
3.3 Summary
In this chapter, we have shown that the prevalent form of CSQ2 glycans in
normal dogs is absent in HF dogs and is replaced with two new pools that accumulate
with different forms of the glycan. The most unprocessed form of CSQ2 accumulated to
as high as 40% of total CSQ2 in only weeks of the induced cardiomyopathy. The most
highly trimmed forms of CSQ2 were virtually absent in HF animals, indicating that CSQ2
was not processed as HF ensued and by the time the tissue was harvested (4 weeks or
greater) (Figure 3-2 panel a). Whether complete loss of this highly processed CSQ2 in
failing hearts was due to normal attrition could not be determined from the data.
Nevertheless, in place of normal low-mass CSQ2, two higher-mass forms of CSQ2
accumulated in HF (Figure 3-2 panel a).

Given the altered patterns of CSQ2

processing, and the reduction in CSQ2 protein levels, and the increase in mRNA levels
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(Figure 3-3 panel b), the data infer an increased breakdown of CSQ2 in HF.
A better understanding of basic ER/SR protein traffic in adult cardiomyocytes is
needed for interpreting the changes in CSQ2 we found in vivo. In Chapters 4 and 5, we
therefore examined where within the cell are found newly formed junctional SR proteins.
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CHAPTER 4
SORTING AND TRAFFICKING OF JUNCTIONAL SR TRANSMEMBRANE
PROTEINS ACROSS ER ALONG MICROTUBULES
4.1 Rationale
SR subdomains form at sites where protein complexes concentrate [26, 187]. In
myocytes, atypical intracellular structure has prevented a clear understanding of the
routes by which ER/SR compartments form and are dynamically maintained.
Relationships between the inner membrane subcompartments in cardiomyocytes have
historically been more defined by ideas of Ca2+ cycling within the cell than by their cell
biological compartmentation or biogenesis. Studies do suggest that even at steady
state, the SR is a dynamic structure, and its motility is regulated by MTs and the
molecular motors dynein and kinesin (kif5b) [188]. Previous studies using the fusion
protein CSQ2-DsRed suggested that its biosynthesis was in or near the nuclear
envelope [116, 117].
To investigate cellular mechanisms for sorting and trafficking proteins to
junctional SR, we expressed canine forms of JCT or TRD in adult rat cardiomyocytes.
Protein accumulation over time was visualized by confocal fluorescence microscopy
using species-specific antibodies.
Hypothesis: Junctional SR transmembrane proteins TRD and JCT synthesis occurs in
juxtanuclear rough ER and traffics along ER and MT pathways to accumulate in
junctional SR
4.2 Results
4.2.1 Species-specific antibodies to junctional SR transmembrane proteins
To validate the relative immunoreactivities of antibodies used in this study, we
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tested relative specificities by immunoblotting against samples from canine and rat heart
microsomes. Anti-JCTdog and anti-TRDdog antibodies exhibited complete specificity to
the canine forms (Table 2-1 and Figure 4-1). These antibodies would therefore permit
the specific detection of acutely expressed canine junctional SR proteins from the
steady-state levels of the native rat heart protein forms. Meanwhile, rat forms JCTrat
and TRDrat can be detected using a second set of antibodies, although anti-JCTrat
detected both forms. We found minor species-specific differences in TRD mobilities but
not JCT (Figure 4-1 panel C).

Figure 4-1. Specificity of anti-TRD and anti-JCT antibodies. Samples (50 g) of canine
heart microsomes (MVc), rat heart microsomes (MVr) and primary rat cardiomyocytes
(HCr) were analyzed by SDS-PAGE (10% acrylamide) and transferred to nitrocellulose.
(A) Amido black stained nitrocellulose, molecular weight markers in kDa. (B)
Immunoblotting with antibodies anti-TRDrat and anti-TRDdog. (C) Immunoblotting with
anti-JCTdog and anti-JCTrat. Molecular weight markers kDa, indicated on the left for each
immunoblot.
4.2.2 Early accumulation of expressed JCTdog and TRDdog at juxtanuclear sites
To visualize the intracellular sites of earliest JCT and TRD accumulation and
early trafficking, we analyzed cultured adult rat cardiomyocytes after 12, 24, 30 and 48h
of overexpression. Confocal images of indirect immunofluorescence were generally
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acquired as a Z-stack covering the height of the cell in contiguous series of optical
slices of 0.5 m thickness, allowing us to most clearly determine ER/SR structures
radiating outward from nuclei.
Figure 4-2. JCT accumulation at
juxtanuclear
sites
Coverslips
containing cardiomyocytes were
fixed following no virus (-) or
treatment with JCT (JCTdog)
adenovirus for 16, 24, or 30 h,
and remaining cells harvested for
immune-blotting.
Cells
were
double-labeled with anti-JCTdog
(green) and anti-JCTrat (red) at
each time point. Fluorescence
images for cells were acquired
using identical settings and
processed offline at the same
time,
to
permit
direct
comparisons. (A) Representative
cells are shown for time points as
indicated 16, 24, and 30 h, either
for JCTdog the green channel (antiJCTdog) alone, or merged with red
JCTrat (anti-JCTrat). Panel c is the
same image as shown in b
following an arbitrary increase in
the signal offline. Panels f and g
are the merge images of d and e, RGB channels. Scale bar, 10 µm. (B) Magnification of
outlined box (panel A-f) showing JCTdog appearing first at juxtanuclear sites. Scale bar 2
µm. (C) Immunoblot analysis of cardiomyocyte protein extracts showing JCTrat and
JCTdog levels with increasing times of JCTdog overexpression. Immunoblot was
performed using anti-JCTrat (detecting both native and expressed forms) and antiJCTdog. Molecular weight marker on the left is 31 kDa.
JCTdog first appeared after 16-24 h of virus treatment, and its early distribution
showed a restricted pattern of puncta that surrounded nuclei, when viewed in an optical
plane through the center of a myonuclei. The most intensely fluorescent puncta were
those that most closely encircled the nucleus (Figure 4-2 panel A). Additional puncta of
lower intensity appeared to radiate away from the nuclear surface along transverse (Z-)
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lines towards the periphery of the cell. JCTdog immunofluorescence co-localized with
that of native JCTrat, validating its passage across, and concentration in, junctional SR.
With increasing incubation times, JCTdog accumulated at greater distances from the
nuclear surface, suggesting a peripherally directed movement of protein across the cell.
By 36-48 h of incubation, the distribution of JCTdog was qualitatively similar to that of
native JCTrat. The time course of JCTdog accumulation observed in the microscope was
validated by immunoblotting of harvested cells (Figure 4-2 panel C) JCTdog levels rose
significantly between 24 and 48 h, commensurate with the accumulation of fluorescent
puncta across the cell periphery.
TRDdog showed a pattern of accumulation that was similar to that of JCTdog.
TRDdog also first appeared in cultured cardiomyocytes around 16-24 h in culture (Figure
4-3). Newly synthesized TRDdog accumulated in cisternae that encircled nuclei at 16 h
when visualized in optical plane of the nucleus (Figure 4-3 panel A). TRDdog and TRDrat
immunofluorescence co-localized and showed a very similar distribution (Figure 4-3
panels B, C) validating an apparent direct passage of TRDdog across, and concentration
in, junctional SR.

Thus, a common pathway and time course JCT and TRD

accumulation across increasingly peripheral junctional SR puncta suggested sites of
biosynthesis close to the cell surface, with an apparent direct membrane trafficking
pathway transversely (radially) across junctional SR.
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Figure 4-3. TRD accumulation at juxtanuclear sites. Coverslips containing
cardiomyocytes were fixed following treatment with TRD (TRDdog) adenovirus for 16, 24,
30, or 48 h, and remaining cells harvested for immunoblotting. Cells were doublelabeled with anti-TRDdog (green) and anti-TRDrat (red) at each time point. Fluorescence
images for cells were acquired using identical settings and processed offline at the
same time, to permit direct comparisons. (A) Representative cells are shown for time
points as indicated for anti-TRDdog alone. (B) Immunofluorescence for native TRD (antiTRDrat) for the16 h time point, typical for all cells. (C) Magnification of outlined box
(panel A, 16 h) showing TRDdog appearing first at juxtanuclear sites. Scale bar 2 µm. (D)
Immunoblot analysis of cardiomyocyte extracts showing TRDdog and TRDrat with
increasing times of TRDdog overexpression, as indicated. The TRDdog immunoblot was
counter-stained with anti-TRDrat to show differences in their respective mobilities.
Molecular weight markers are shown in kDa on the left.
4.2.3 In situ interaction of JCTdog and TRDdog with CSQ2-DsRed in rough ER
Although newly-synthesized JCT or TRD formed a punctate pattern by 48 h
detectable amounts of protein could be observed even closer to the nuclear surface at
early time points, suggesting that newly formed junctional SR puncta were distal to the
actual sites of biosynthesis.
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Figure 4-4. TRD and JCT move along a common pathway to populate junctional SR.
Cardiomyocytes were not treated
(-), or co-treated with TRD and
JCT adenoviruses for 18, 24 or
48
h,
then
fixed
for
immunostaining and remaining
cells
harvested
for
immunoblotting. (A) Adult rat
cardiomyocytes
coimmunostained with anti-TRDdog (green)
and anti-JCTdog (red); nuclei are
blue. Scale bar, 10 µm. (B)
Magnification of outlined box
(panel A). Scale bar, 2 m. (C)
Upper Stained nitrocellulose
transfer of protein extracts from
untreated and treated cells at
various time points as indicated.
Lower
Autoradiogram
from
immunoblot with anti-TRDdog
(upper band) and anti-JCTdog
(lower band) showing canine
protein
expression
levels.
Molecular weight markers are
indicated on the left.
To further investigate the sites of junctional SR protein biosynthesis, we
compared early JCT and TRD sites of accumulation with the bright red DsRed
fluorescence that accompanies accumulation and concentration of CSQ2-DsRed near
its site of biosynthesis [85, 171]. Co-expression of either TRD or JCT with CSQ2DsRed led to co-localization of their immunofluorescence with CSQ2-DsRed polymers
in the nuclear envelop (Figure 4-5 panel A). Prior to formation of CSQ2-DsRed red
polymers at 24 h, JCT and TRD showed somewhat typical juxtanuclear patterns of
junctional SR filling. However, by 48 h, JCT and TRD had accumulated to high levels in
and around the nuclear envelope, co-localized with CSQ2-DsRed.
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Figure 4-5. In situ interactions of JCT and TRD with CSQ2-DsRed at juxtanuclear sites.

Co-expression of CSQ2-DsRed was carried out with either JCT or TRD for
varying times, as indicated, then cells were fixed for immunostaining and
remaining cells harvested for immunoblotting. (A) Cardiomyocytes co-expressing
CSQ2-DsRed and either JCT, TRD, or delTRD, for 24 or 48 h.
Immunofluorescence staining using either anti-JCTdog or anti-TRDdog is shown
in green, CSQ2-DsRed is red. Scale bar, 10 mm. (B) Cells were not treated (-) or
were treated with JCTdog and CSQ2-DsRed adenoviruses for the indicated
number of hours. Immunoblot data for cells were obtained using a mixture of antiCSQ2 and anti-JCTdog antibodies. (C) Cells were not treated, lane 1; treated
with TRDdog and CSQ2-DsRed adenoviruses for 48 h, lane 2; or were treated
with delTRD and CSQ2-DsRed adenoviruses for 48 h. Immunoblot data for cells
were obtained using a mixture of anti-CSQ2 and anti-TRDdog antibodies. A band
that appears in all lanes near 40 kDa (asterisk, *) was not seen in other
experiments.
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Figure 4-6. CSQ2DsRed-containing
ER traffics between
myonuclei in line
with MTs. Cardiomyocytes
were
cultured for 48 h
with
Ad.CSQ2DsRed adenovirus,
and fixed before
immunostaining with
anti-alpha
tubulin
(green). (A) CSQ2DsRed fluorescence
shows high levels of
accumulation
in
juxtanuclear
ER
cisternae, but also
within
longitudinal
tubules
of
ER
extending between
the two nuclei. (B)
Double labeling of
CSQ2-DsRed (red)
and α-tubulin immune-fluorescence shows abundant MTs extending between nuclei.
Anti-tubulin immunofluorescence (C) of the panel B inset shows a complex scaffold that
might support ER tubules containing CSQ2-DsRed (D). Scale bar A, B 10 m and D, 5
m.
To show that newly made TRD was binding to CSQ2 through its wellcharacterized interaction domain [104], we compared the effect of CSQ2-DsRed on
trafficking of newly accumulated delTRD, a deletion mutant of TRDdog that has absent the
canonical CSQ2-binding site.

del

TRD showed little co-localization or restricted

anterograde movement with CSQ2-DsRed (Figure 4-5 panel A). These data suggested
that CSQ2-DsRed, TRD, and JCT are biosynthesized at a common intracellular site,
likely corresponding to the nuclear envelope. These data also demonstrate that both
JCT and TRD can bind to CSQ2 in situ.
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Figure 4-7. TRD is retained by
its
in
situ
binding
to
polymerized CSQ2-DsRed in
the
smooth
ER
lumen.
Cardiomyocytes were cultured
with adenoviruses encoding
CSQ2-DsRed and TRD for 3648 h, which led to co-localized
protein accumulation around
and
between
myonuclei.
CSQ2-DsRed,
once
polymerization occurs, serves
as a marker for early ER. (A)
TRD retained in large part
within this series of smooth ER
membranes, depending upon
the rates of TRD synthesis and
trafficking. (B, C) Individual
color channels for CSQ2DsRed (red channel) or TRD
(green channel) are shown in
black and white (D) At 36 h of
expression, CSQ2-DsRed was
present
in
the
nuclear
envelope, but also present in
the ER tubules aligned axially across the cell (white lines in inset. TRD puncta (green)
were aligned along these smooth SR tracts suggesting that smooth ER may contribute
to sorting of TRD to junctional SR sites (E) Punctate TRD immunofluorescence always
co-localized with CSQ2-DsRed in nuclear envelope but some portion generally
appeared to outpace CSQ2-DsRed, leading to green puncta with little CSQ2-DsRed
fluorescence. Scale bar 10 m, A-C; 5 m, D, E.
4.2.4 Morphological distinctions between smooth ER and junctional SR
In this study, we found that longer periods of CSQ2-DsRed accumulation
produced red fluorescent polymers that populated ER tubules visualized along MTs
between and surrounding the two myonuclei (Figure 4-6). This CSQ2-DsRed-positive
ER often appeared as circular or polygonal tubules, presumably depending upon its
orientation in optical slices. Meanwhile, around nuclei, and particularly between nuclei,
CSQ2-DsRed-containing

ER

appeared

as

intertwined

tubular

and

polygonal

membranes (Figure 4-7 panels B, D). The underlying MT network in these regions
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suggested that these more extensive smooth ER components might lie along a dense,
longitudinally directed and looping MT network. (Figure 4-7 panels B, C).
To investigate in more detail the ER accumulation sites of CSQ2-DsRed with
those of newly synthesized TRD and JCT, we examined the CSQ2-binding deletion
mutant

del

TRD, to prevent its strong in situ interaction with CSQ2-DsRed. Generally,

after 36 h of incubation with the adenovirus, CSQ2-DsRed had developed its red
polymerization in juxtanuclear cisternae (Figure 4-8 panel A, red fluorescence), during
which time

del

TRDdog (Figure 4-8 panel A, green fluorescence) has developed a

distribution pattern approaching that of native steady-state junctional SR proteins.
Expressed alone,

del

TRDdog produced a time-dependent change in fluorescent puncta

that was similar to that of wild type TRDdog and JCTdog proteins (APPENDIX C Figure A2). When co-expressed with CSQ2-DsRed however,

del

TRD immunofluorescence and

DsRed red fluorescence labeled morphologically distinct subcompartments (Figure 4-8
panels B, C).

CSQ2-DsRed was localized to the nuclear envelope and smooth

longitudinal ER tubules aligned between and around nuclei along MT-like pathways.
However,

del

TRD immunofluorescence was generally very low in CSQ2-DsRed-

containing smooth ER, instead concentrating in puncta. Longer incubation times (~72
h) led to increased fluorescence intensity of juxtanuclear tubules of CSQ2-DsRed, yet
junctional SR sites marked by

del

TRD immunofluorescence still maintained a distinct

separation from DsRed fluorescence.
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Figure 4-8. The CSQ2del
binding
mutant
TRD
readily crosses the smooth
ER to concentrate at sites
of
junctional
SR.
Cardiomyocytes
were
cultured with adenoviruses
encoding CSQ2-DsRed and
TRD for 48 h. (A) CSQ2DsRed
fluorescence
surrounds each myonuclei,
but little overlap is seen
with
green
anti-TRD
immunofluorescence
(delTRD). (B-B2 and C-C2)
Enlarged portions of the two
perinuclear regions (insets
panel A) are shown with the
individual
channels
for
del
CSQ2-DsRed and
TRD.
CSQ2-DsRed was highly
enriched in areas around
and between nuclei, and
greatly reduced in more
distal ER/SR compartments
(panels B1 and C1). TRD
immunofluorescence
(panels B2 and C2) shows
the opposite effect: reduced
immunofluorescence
in
CSQ2-DsRed compartments (smooth ER), with concentrated junctional SR puncta
originating in tubules outside of the perimeter of ER defined by CSQ2-DsRed. Transition
of smooth ER-to-junctional SR (arrows) (D) TRD after 36 h overexpression can be seen
traversing the smooth ER as it traffics toward junctional SR enrichment (E) After 48 h,
the smooth ER becomes expanded by CSQ2-DsRed at the same time as junctional SR
puncta appear at further distances from the nuclear surface.
Transitions from the more longitudinally oriented CSQ2-DsRed-positive ER, to
transversely aligned puncta containing

del

TRDdog immunofluorescence, generally

occurred over a radial distance of only a few hundred nanometers. This indicated that
del

TRD was retained at lower levels in the proximal CSQ2-DsRed that did not develop

into fluorescent puncta. Beyond a defined distance from the central axis of the cell,
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del

TRD began showing punctate junctional SR sites along the MTs, taking on the

punctate appearance of junctional SR (Figure 4-8 panel D). The fundamental difference
between smooth ER-filled tubules and the more distal junctional SR puncta appeared
therefore to correspond to whether a deposition and concentration of ER cargo (TRD
and JCT) occurred in the vicinity of the Z-line. Since TRD and JCT readily sort and
traffic to junctional SR, and polymerized (red) CSQ2-DsRed concentrates almost
exclusively in a more proximal ER subcompartment that extends away from
juxtanuclear rough ER, we propose that the CSQ2-DsRed is a unique marker of a prejunctional SR (cardiac rough ER and cardiac smooth ER).
4.2.5 Inhibition of anterograde trafficking by nocodazole
Trafficking of JCT and TRD away from the nuclear envelope occurs within ER
tubules that are known to be associated with MTs, along longitudinal and transverse
pathways, we predict that trafficking to junctional SR would require a MT platform from
which molecular motors could carry the junctional SR cargo.
To determine the effects of MT disruption on early accumulation and initial
trafficking steps of JCT and TRD, we used nocodazole.

Effects of nocodazole on

disruption of junctional SR have been previously reported [188]. Immunofluorescence
of both α-tubulin and β-tubulin was examined in the adult rat cardiomyocyte, and
differences have been reported in the monomer distribution as shown (Figure 4-9).
Using each of two different anti-tubulin antibodies, a high degree of MT disruption was
seen after as little as 2 h incubation with 20 M nocodazole (Appendix C Figure A-3).
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Figure 4-9. Nocodazole disrupts
anterograde
movement
of
junctional SR proteins. Immunofluorescence performed on adult
rat cardiomyocytes untreated (-)
or treated (+) with nocodazole
(20 M). Cells were fixed and
stained after 48 h in culture. (A)
Cardiomyocytes treated with
Ad.TRDdog and stained with antiTRDdog (green). Cardiomyocytes
treated with Ad.JCTdog and
stained with anti-JCTdog (green).
Cardiomyocytes co-treated with
Ad.TRDdog and Ad.JCTdog and
stained with anti-TRDdog (green)
and anti-JCTdog
(red) (B)
Magnification of outlined box
from panel B showing TRDdog.
(C) Immunocytochemistry on
cardiomyocytes
showing
αtubulin (green) and β-tubulin
(red). Scale Bar 10 m in A, C, 2
m in B.

Although MT structure was overtly disrupted by 2 h of 20 µM nocodazole,
changes in the overall patterns of JCT and TRD puncta were not obvious at the light
microscope level (Appendix C Figure A-3). Therefore, to ascertain the effects of MT
disruption on JCT and TRD trafficking, we examined whether nocodazole would alter
the sites of protein accumulation over the entire period of time during which JCT and
TRD would acquire their normal junctional SR distribution. Nocodazole was therefore
added to cells after only 16 h in culture. Such extended periods of MT disruption largely
prevented JCT and TRD from leaving their sites of synthesis.

These treatments

resulted in bright fluorescent rings of juxtanuclear ER clusters as opposed to the
anterograde trafficking seen in untreated cardiomyocytes (Figure 4-9 panel B). Levels
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of JCT (Appendix C Figure A-3 panel C) and TRD (data not shown) remained similar in
nocodazole treated and untreated cells. The data suggested that the disruption was
mostly affecting the transport of newly synthesized proteins and not their steady state
distributions.
4.3 Summary
In this chapter, we showed how junctional SR protein biogenesis begins in the
nuclear envelope using immunofluorescence analyses of protein expression. Newly
synthesized JCT and TRD appeared by 24 h as bright fluorescent puncta close to the
nuclear surface, decreasing in intensity with increasing radial distance. With increasing
time (24-48 h), fluorescent puncta appeared at further distances from the nuclear
surface, resembling steady-state patterns of junctional SR. CSQ2-DsRed prevented
anterograde traffic of newly made TRD and JCT. In situ binding of TRD to CSQ2DsRed and effects on its trafficking were abolished if a form of TRD was used in which
CSQ2-binding sites are removed (delTRD).
Double labeling studies confirmed that

del

TRD first concentrates in junctional SR

puncta that are morphologically distinct from CSQ2-DsRed sites, although

del

TRD also

accumulated at low levels in these earlier secretory subcompartments. Besides being
localized to the nuclear envelope (rough ER), CSQ2-DsRed labeled a novel smooth ER
network that surrounds nuclei and connects the nuclear axes.
The transmembrane junctional SR proteins transit across perinuclear smooth ER
that extend along microtubules away from the nucleus, concentrating only where ER
trafficking crosses Z-lines. ER/SR protein traffic required MTs, as nocodazole treatment
led to disruption and minimal anterograde protein movement of both JCT and TRD, with
accumulations close to the nuclear envelope.
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CHAPTER 5
TRAFFICKING OF THE LUMINAL SR PROTEIN CSQ2
5.1 Rationale
The luminal junctional SR protein CSQ2 was discovered many years prior to the
transmembrane CSQ2-binding proteins JCT and TRD (Chapter 4), and in many ways is
the most enigmatic of the group of proteins classically known to enrich in junctional SR
subcompartments. As a luminal protein, it is not restricted by the dynamics of the lipid
bilayer, and should be capable of faster trafficking through secretory pathway lumens.
At the same time, because it contains no known retrieval sequences, it should in
principle be secreted from the cardiomyocyte - but apparently is not. We have shown
that the retention of different forms of the protein CSQ (e.g. CSQ1, CSQ2, and CSQ2DsRed) is uniquely determined by their polymerization, which is sensitive to levels of
Ca2+ and ionic milieu [19].
ER trafficking of luminal cargo requires communication with cytosolic trafficking
proteins.

To define the biosynthetic trafficking pathway for luminal junctional SR

proteins, we expressed canine CSQ2 and detected it with canine-specific protein
antibodies. These studies extend the data obtained for JCT and TRD, and present a
wider view of junctional SR protein trafficking and junctional SR compartmentation.
Hypothesis: CSQ2, a luminal junctional SR protein is synthesized in the juxtanuclear
rough ER and traffics through the same ER/SR pathways defined by our studies on the
transmembrane proteins JCT and TRD.
5.2 Results
5.2.1 Detection of CSQ2dog using species-specific antibodies
To determine the specificity of the antibody utilized in the detection of expressed
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canine CSQ2, immunoblot analysis was performed on protein samples from canine and
rat microsomal vesicles.

In comparison to canine microsomes where CSQ2 was

detected, no band was detected in rat microsomes using anti-CSQ2dog antibody (Figure
5-1 panel B). Thus, this data shows that the antibody used for detection of CSQ2 is
highly specific to the expressed canine form with relatively no cross reactivity with the
rat form of the protein. Meanwhile, rat forms of CSQ2 can be detected using a second
antibody that reacts with both canine and rat forms.
When immunocytochemistry was performed on adult rat cardiomyocytes
expressing CSQ2 for 48 h, CSQ2dog co-localized with the endogenous native rat form of
the protein at junctional SR sites and displayed a similar subcellular distribution (Figure
5-1 panel C). However, displayed a similar but antibody specific staining.

C

Figure 5-1. Specificity of anti-CSQ2
antibodies. Samples (50 g) of
canine heart microsomes (MVc) and
rat heart microsomes (MVr) were
analyzed by SDS-PAGE (10%
acrylamide) and transferred to
nitrocellulose. (A) Amido black
stained nitrocellulose. (B) Immunoblotting of CSQ2 (arrowhead) using
and
anti-CSQ2rat
anti-CSQ2dog
antibodies. (C) Immunofluorescence
of CSQ2 in cultured adult rat
cardiomyocytes
treated
with
Ad.CSQ2 for 48 h using anti-CSQ2
(green) and anti-CSQ2rat (red). Scale
Bar 10 m.

5.2.2 Determination of CSQ2 initial sites of accumulation
To determine the biosynthetic pathway luminal junctional SR proteins follow, a
time course of canine CSQ2 expression was performed over 48 h in adult rat
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cardiomyocytes.

To

visualize

the

CSQ2

accumulation,

cultured

rat

adult

cardiomyocytes were analyzed after 16, 24, 30 and 48h of overexpression. Confocal
images of indirect immunofluorescence were generally acquired as a Z-stack covering
the height of the cell in contiguous series of optical slices of 0.5 m thickness.
In contrast to accumulation at juxtanuclear sites for the transmembrane junctional
SR proteins TRD and JCT, CSQ2 was widely distributed throughout the cell after only
16 h, accumulating at junctional SR sites with no concentration around the nucleus
(Figure 5-2). We believe that the rapid transit and approach to steady state distribution
reflects the differences between the transport of luminal and transmembrane ER/SR
proteins. Thus far, these data do not support our hypothesis that all junctional SR
proteins are made in a common juxtanuclear sites
Also, unlike the distinct juxtanuclear localization of the fusion protein CSQ2DsRed (see Chapter 4 section 4.2.2), CSQ2 (wild-type) was widely distributed. The
differences in localization for wild-type versus CSQ2-DsRed likely reflect their
polymerization-dependent localizations. This would explain why CSQ2-DsRed remains
in rough ER while native CSQ2 traffics more distally to contiguous junctional SR sites.
Given the rapid transit of CSQ2 across ER /SR compartments, we hypothesized
that the luminal protein trafficking was too rapid to permit juxtanuclear accumulation.
Therefore, to visualize the earliest sites of CSQ2 accumulation, overexpression of
CSQ2 was performed at higher adenoviral concentrations 2x and 5x.
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Figure 5-2. Time course of CSQ2 accumulation at junctional SR sites. Coverslips
containing cardiomyocytes were removed and fixed following treatment with Ad.CSQ2
for 16, 24, 30 and 48 h and remaining cells harvested for immunoblotting. (A-D)
Immunofluorescence of CSQ2 (green) and nuclei (blue) at different time points, cells
were stained with anti-CSQ2dog. Scale bar 10µm. (E) Amido Black stained nitrocellulose
of protein extracts from cardiomyocytes corresponding to 16, 24, 30 and 48 h of
Ad.CSQ2 treatment. (F) Immunoblot analysis of cardiomyocyte protein extracts using
anti-CSQ2 showing CSQ2 levels with increasing times of canine CSQ2 overexpression.
Molecular weight markers (kDa) indicated on the left.
In contrast to CSQ2 1x adenoviral treatments, higher juxtanuclear CSQ2
immunofluorescence signals were detected in cardiomyocytes that received 2x and 5x
Ad.CSQ2 (Figure 5-3).

The distribution of CSQ2 fluorescence at 5x Ad.CSQ2

treatments displayed a membrane-subcompartment-filled in juxtanuclear membrane
sites and not a strictly punctate pattern as seen at distal sites. These data support the
idea that CSQ2 is also synthesized in and around the nuclear envelope, although the
levels of overexpression needed to visualize it are too high to warrant detailed analysis.
Interestingly, the changes in ER morphology that accompanied the highest levels of
CSQ2 overexpression in the juxtanuclear area appear somewhat similar to the
increased ER cisterna observed with CSQ2-DsRed expression (Chapter 4 section
4.2.4).
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Figure 5-3. Higher rates of CSQ2 biosynthesis create higher fluorescence intensities at
juxtanuclear sites. Coverslips containing cardiomyocytes were removed and fixed
following treatment with Ad.CSQ2 for 48 h at 1x, 2x and 5x, remaining cells were
harvested for immunoblotting (A) Immunofluorescence of CSQ2 (green) in adult rat
cardiomyocytes detected using anti-canine CSQ2, following 1x, 2x and 5x Ad.CSQ2
treatments for 48 h. Nuclei (blue) are stained with DAPI. Scale bar 10m (B) Enlarged
portions of the perinuclear regions (panel A, insets) (C) Autoradiogram showing CSQ2
levels. Protein extracts are from cardiomyocytes cultured for 48 h either untreated or
treated with Ad.CSQ2-WT at 2x and 5x, respectively. Molecular weight markers in kDa
indicated on the left. (D) Fluorescence intensity of CSQ2. Quantification of fluorescence
from CSQ2dog expression (in 10 cells /condition) was measured as a function of
transverse distance (m) from the nuclear edge in 48 h cultured cardiomyocytes. Values
of fluorescence intensity are relative to the intensity at the edge of the cell.
5.2.3 In situ interaction of TRDdog with CSQ2
Previous studies have demonstrated in vitro interaction between proteins that are
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part of the Ca2+ release complex. Moreover, we have shown here that CSQ2-DsRed
expression led to the complete retention of TRD and JCT in and around the nuclear
envelope. We therefore, sought to determine whether CSQ2 accumulation, localization
and rates of trafficking would be affected by the overexpression of TRD or vice versa.
Primary adult rat cardiomyocytes were co-treated with Ad encoding canine CSQ2 and
TRD. Expressed protein levels were detected using canine specific anti-CSQ2 and antiTRD, immunoblotting showed an increase in protein levels at 48 h compared to 24 h
(Figure 5-4, panel A).

Immunocytochemistry showed no accumulation of CSQ2 at

juxtanuclear sites upon co-overexpression with TRD (Figure 5-4, panels B, C), unlike
CSQ2-DsRed co-overexpression that concentrated TRD at juxtanuclear rough ER sites.
The slower trafficking transmembrane TRD did not exhibit an overt effect on the faster
trafficking of luminal CSQ2. This may be due to the rapid passage and dispersal of
CSQ2 through the SR/ER lumen away from the membrane surface and the nuclear
envelope.
5.2.4 Effect of nocodazole on junctional SR sites and CSQ2 trafficking
MTs are known to interact with the ER and are involved in the extension of ER
tubules. To determine the effect of nocodazole on CSQ2 accumulation at junctional SR
sites, cells expressing both CSQ2dog and TRDdog were treated with 20 M nocodazole
(Figure 5-4, panel D). Immunofluorescence analysis showed a distinct effect on the
transmembrane protein TRDdog but with minimal to no effect on the expressed luminal
protein CSQ2. Nocodazole also had no effect on endogenous junctional SR containing
CSQ2 localization upon nocodazole treatment (Appendix C Figure A-4). The lack of
effect of nocodazole on CSQ2 trafficking or native junctional SR puncta compared to
TRD anterograde trafficking may be due to the presence of multiple cytoskeletal
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structures that help to maintain the more distal subcellular membrane compartments
[127].

Figure 5-4. CSQ2 maintained independent transit when co-expressed with TRD and
was not similarly disrupted by nocodazole treatment. Coverslips containing
cardiomyocytes were removed and fixed following culture for 24 or 48 h and co-treated
with both Ad.CSQ2, Ad.TRD and with or without nocodazole, remaining cells were
harvested for immunoblotting (A) Autoradiogram showing protein levels of expressed
CSQ2 and TRD. Protein extracts were obtained from cardiomyocytes co-treated with
Ad.CSQ2 and Ad.TRD for 24 and 48 h. Proteins detected using anti-CSQ2dog, and antiTRDdog.
Molecular weight markers (kDa) indicated on the left. (B-D)
Immunofluorescence of CSQ2 (green) and TRD (red) in cardiomyocytes co-treated with
Ad.CSQ2 and Ad.TRD for 24 h or 48 h. (B) Cultured for 24 h, (C) Cultured for 48 h (D)
cultured for 48 h and treated with nocodazole (20 µM). Nuclei (blue) are counter-stained
with DAPI. Scale bar 10 m.
5.3 Summary
In this study, we examined the luminal SR protein CSQ2 biogenesis. CSQ2
established steady state distribution and did not show juxtanuclear accumulation at 1x
CSQ2dog expression. Sites of biosynthesis were less prominent for CSQ2 because it is
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luminal (compared to TRD or JCT), and the wild-type forms of CSQ2 cannot polymerize
in the juxtanuclear compartment. Nevertheless, higher CSQ2 expression levels were
able to validate the hypothesis that junctional SR proteins have a common
biosynthetic/secretory pathway. The data provides a consistent model of ER and SR
transmembrane (Chapter 4) and luminal (Chapter 5) protein transport across the
cardiomyocytes, and a new understanding of pathways by which cellular Ca2+ handling
protein complexes can be maintained and modified.
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CHAPTER 6
DISCUSSION
Crucial distribution and localization of proteins within the adult cardiomyocyte
inner membrane system are the result of the ongoing sorting and trafficking of proteins.
Many resident proteins of the ER/SR and sarcolemmal membranes continually take part
in this membrane protein traffic, yet very little is known about these processes in the
heart.

A range of biochemical and immunological techniques were used in this

Dissertation to develop a basic model of protein trafficking in the cardiomyocyte that
may also explain fundamental changes observed in intact hearts during failure.
6.1 CSQ2 mass redistribution in two types of cardiomyopathies
In Chapter 3, we evaluated CSQ2 purified from heart tissue following two
different types of induced cardiomyopathies. Remarkably, we found similar patterns of
mass redistribution in the two disparate types of cardiomyopathies when compared to C
mongrel dogs.

The changes in mongrel dogs mimicked the changes previously

reported for tachypaced beagles [178], with a series of interesting new findings.
Overall, our results suggest that a common mechanism for change in CSQ2 mass
(glycosylation and phosphorylation) and turnover exists that is independent of the
pathologies that lead to the syndrome of HF (Figure 3-1 panel b), likely reflecting an
adaptive response of the distressed myocardium. These studies involved changes in
two cardiac pathological mechanisms by which an animal is put into heart failure,
apparently manifested through a common biochemical and cell biological change.
Hearts from HFi dogs reportedly exhibit increased LV wall thickening (27%) and
increased heart weight to body weight ratios (18%) [165], whereas tachypacing is
marked by LV wall thinning, LV dilatation, and reduced heart weight [184]. HFt hearts
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can develop LV hypertrophy following resumption of normal pacing [189], suggesting
that a single program of remodeling develops that is independent of the induction route.
On the other hand, the different types of hypertrophy reported for HFt and HFi tissues
might explain the similar but distinct changes in CSQ2 mannose trimminig reported
here.
The single biological change might be related to changes known to occur as part
of cardiac hypertrophy. Mechanisms for cardiac hypertrophy remain unclear but are
likely to involve formation of new Ca2+ microdomains within the ER or SR of the inner
membranes of the cardiomyocyte [112, 190]. Changes in CSQ2 glycan structure in
failed heart tissue correspond to changes brought about by the formation of new protein
that undergoes less glycan processing.
CSQ2 molecules in the canine heart undergo co-translational N-linked
glycosylation on

316

Asn [167]. In addition, canine CSQ2 molecules are phosphorylated

on 0,1,2, or 3 serines contained within the CSQ2-specific C-terminal cluster 378,382,386Ser
[167, 191]. This modification is thought to be carried out by a cytosolic protein kinase
CK2, also occurring co-translationally [183]. Therefore, the greatest posttranslational
mass for CSQ2 is 47,478 Da, which contains 9 mannoses and 3 phosphates. This form
of CSQ2 ordinarily only accumulates at high relative levels when canine cDNA is
adenovirally-overexpressed in non muscle cell lines [167]. In contrast, very little of this
unprocessed form is found in the mammalian heart [167, 179]. Most CSQ2 in the heart
is highly mannose-trimmed and relatively dephosphorylated [179]. We believe that he
degree of posttranslational processing is likely to reflect critical regulatory roles in CSQ2
turnover. Mannose trimming of N-linked glycans is likely to reflect CSQ2 degradation
[180, 181], whereas CK2 phosphorylation states may reflect CSQ2 turnover [179, 183].
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The mechanisms underlying the CSQ2 mass redistribution are likely to lie in
CSQ2 cellular processing, from its biosynthesis, to its accumulation in ER/SR
subcompartments, to its degradation. One possibility for the changes is that the two
accumulated pools emanate from two distinct sites of CSQ2 biosynthesis (rough ER),
one that is roughly common to both normal and HF myocardium (Pool I), and one that is
activated only in cardiomyopathy states of the myocardium (Pool II).

The lack of

posttranslational processing of Pool II suggests either that this CSQ2 is not being
transported to junctional SR, or perhaps degrades before undergoing further mannose
trimming.

In studies aimed at elucidating sites for junctional SR protein synthesis

(Chapter 4 and 5), we found no evidence to support more than a single subcellular site.
We cannot however, exclude the possibility that additional sites of biosynthesis arise or
become activated in cardiomyopathy.
An immunofluorescence analyses of thin tissue sections was aimed at
determining whether quantifiable differences could be detected across the cell, from
juxtanuclear rough ER transversely to the cell surface. The lack of significant changes
in CSQ2 immunoreactivity in C and HF tissue may suggest that a more complex
subcellular distribution underlies the observed mass redistribution.

In our new

trafficking model, CSQ2 and other SR proteins could exhibit differences in a smooth ER
to junctional SR step that could also explain the changes in its glycan structure. It will
be interesting to extend the immunofluorescence analyses to include changes that are
reflective of MT trafficking or smooth ER transport; new ideas that based upon our
proposed model of membrane protein trafficking.
The two CSQ2 mass pools could also develop from a single site of CSQ2
biosynthesis, after which differences occur in the rates of anterograde trafficking.
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Different rates of anterograde transit through the cardiac secretory pathway might result
from different rates of CSQ2 translocation through CK2-modified translocons [183, 192,
193], or as a result of increased retention of CSQ2 transcripts in rough ER following
CK2 phosphorylation [183]. We previously reported that CSQ2 in the failing beagle
heart showed increased phosphorylation on protein kinase CK2-sensitive sites [178],
and we have also shown that CK2 phosphorylation of CSQ2 can result in increased ER
retention [183].

Calnexin, another resident ER/SR protein substrate for CK2, may

associate with the translocon upon CK2 phosphorylation [193]. A broader role for CK2
activation of cardiac hypertrophy was recently predicted, based upon a hypertrophic
activation of p27/Kip1, which leads to CK2 dissociation and activation [194]. This model
of cardiac hypertrophy involves the intriguing connection between p27/Kip1 activation of
cell proliferation (GS-phase transition) in dividing cells, and activation of hypertrophy
in the non-dividing cardiomyocyte.
Finally, accumulation of CSQ2 in a second metabolic pool might represent the
effects of T-tubule changes. Loss of normal T-tubule morphology has been widely
reported in HF based upon microscopic visualization in tissue and cultured cells of
mammalian HF models [195-197].

Retraction of the transverse invaginations of

sarcolemma leaves a disorganized ultrastructure with orphaned RyRs that contribute to
arrhythmogenesis through under-regulated sparks [195]. With loss of triggered Ca2+
release, CSQ2 might play a more prominent role in regulation of SR Ca2+ release in
RYRs orphaned by T-tubular reorganization. Junctophilin-2, a junctional SR protein that
forms a critical connection to T-tubules, is thought to play a role in T-tubule
reorganization [198]. How and whether such changes would affect other junctional SR
proteins or CSQ2 processing is not known. Data reported here would represent the first
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evidence for specific changes in junctional SR protein processing with T-tubular change
in vivo.
6.2 Junctional SR subdomains: protein trafficking and accumulation
In the studies described in Chapter 4 and 5, we overexpressed JCT, TRD and
CSQ2 in cultured adult rat cardiomyocytes. A putative transport pathway that would
populate successive junctional SR subcompartments has not been previously
described, primarily because little attention has been given to the specialized cell
biology of the cardiomyocyte. In these studies, we were able to show evidence for
synthesis in and around the nuclear envelope.

In addition, we established CSQ2-

DsRed as a marker for a novel compartment based upon double labeling with either
TRD or delTRD.
Studies of SR subcompartment biogenesis have mostly examined the change in
subcompartmentation during muscle cell differentiation, and while those studies can
provide insights, they are not aimed at the fundamental questions of cardiac SR biology
of the adult cardiomyocyte.
cardiomyocytes.

In our studies we specifically studied primary adult

Newly synthesized TRD and JCT generated immunofluorescent

puncta close to the nuclear surface 18-24 h post-adenoviral expression, as did CSQ2
but only at accelerated rates of synthesis. Data obtained for TRD, JCT and CSQ2
corroborate previous findings of CSQ2-DsRed synthesis within cisternae that surround
myonuclei, generating a model of common trafficking for all junctional SR proteins.
In situ interactions between TRD or JCT and CSQ2-DsRed, and effects of
nocodazole on trafficking, suggested that a smooth ER likely underlies all membrane
protein trafficking radially and axially away from the nuclear envelope, maintaining
junctional SR protein levels through selective retention. ER transmembrane protein
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traffic requires intact MTs, as nocodazole treatment led to loss of anterograde JCT and
TRD traffic away from the nuclear envelope.

Disassembly of MTs prevented

anterograde trafficking, leading to build-up of protein in the nuclear envelope as
predicted by our general model.
Given that CSQ2-DsRed maintains ability for rapid in situ Ca2+-binding and
release around the nucleus [171], we reasoned that the fusion protein CSQ2-DsRed
might affect its well-established in vitro binding partners TRD and JCT. Indeed, rough
ER-localized CSQ-DsRed was able to form a veritable net that prevented anterograde
trafficking of JCT and TRD. Upon co-expression of CSQ2-DsRed with TRD and/or JCT,
anterograde trafficking to junctional SR was completely inhibited, and JCT and TRD
were retained within the nuclear envelope and juxtanuclear membranes. Under these
conditions, JCT and TRD did not show the punctate staining of junctional SR, but
collected to a high level in juxtanuclear cisternae characteristic of CSQ2-DsRed and the
rough ER. Lack of CSQ2-DsRed binding to delTRDdog, prevented retention of TRD in the
nuclear envelope, but did not alter its concentration in junctional SR puncta, suggesting
that the KEKE-motif that binds CSQ2 in vitro [104] in TRD (and presumably JCT) is not
necessary for its targeting and concentration in junctional SR.

Wild-type CSQ2,

however, was not retained by the slower-trafficking TRD. Since in situ interactions were
shown to be able to occur, the lack of interaction between newly made transmembrane
TRD and the newly made luminal CSQ show how protein interactions within the
secretory pathway require some spatial coordination, a situation that must occur in vivo.
The amount of time needed for TRD and JCT to accumulate to levels sufficient
for confocal imaging (12-16 h), and the time intervals of ~12 h needed for seeing
changes in protein localization indicative of its trafficking, reflect the passage through
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the lipid bilayer and across longitudinal tubules of ER. JCTdog and TRDdog
immunofluorescence traverses the nuclear envelope (rough ER) with little retention, yet
areas of concentrated protein can be seen in the nuclear envelope, which appear to
represent an initial sorting step from which transit is launched. Visualization of JCTdog
or TRDdog within the nuclear envelope required binding it to the CSQ2-DsRed polymer
that never leaves the ER, or addition of nocodazole to disassemble its anterograde
escape route.
An alternative explanation for the observed time-dependence in accumulation is
a rate-limiting mRNA transport step. In such a model of our data, RNA would have
been transcribed and spliced close to the nuclear surface; mRNA would then be
transported along MTs aligned along Z-lines. In this paradigm, protein synthesis would
presumably occur at successive junctional SR puncta over 48 h. Metsikko and coworkers hypothesized a specialized mechanism for “Ca2+-handling” proteins in cultured
skeletal muscle myotubes. They described a subcellular localization for CSQ1 and
SERCA mRNA using electron microscopic in situ hybridization [199]. However, the
differential binding of TRDdog and

del

TRDdog to perinuclear CSQ2-DsRed, indicate that

the rate of TRD accumulation across the cell interior is dependent upon anterograde
protein traffic instead of a putative cytosolic mRNA transport.
Smooth extensions of the rough ER membrane traffic proteins away from the
nucleus along microtubules radially along Z-lines, as well as longitudinally (axially). The
data suggest that retention of junctional SR cargo proteins near T-tubules occurs via
this ER traffic.

ER tubule extension may occur in response to MT polymerization

through attachment of ER to MT tips. Membrane trafficking and organization has been
linked to microtubule organization [146, 200]. MTs and the molecular motors dynein
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and kinesin are thought to regulate the dynamic changes that are part of steady-state
SR biology [188]. The most common mechanism for MT-based transport is through
cargo association either directly or indirectly with motor proteins [201]. We hypothesize
that following protein maturation in juxtanuclear rough ER cisternae, ER tubules or
vesicles containing transmembrane JCT and/or TRD traffic towards Z-lines along MTs
(Figure 4-9). Here we showed that upon 36 h treatment with the MT disrupting agent
nocodazole, newly synthesized TRD and JCT failed to traffic beyond the nuclear
envelope, so that newly made JCT and TRD failed to develop and populate
characteristic junctional SR puncta.

This disruption of junctional SR population

suggests that a critical MT motor-associated transport is essential for delivery of these
newly synthesized proteins to the junctional SR sites.
Vega et al examined motile SR boutons in the SR of adult ventricular myocytes
labeled by Ad overexpression of red fluorescent protein fused to the well-known ERretrieval tetrapeptide (RFP-KDEL) [188] (-KDEL ER retrieval discussed in Chapter 1,
section 1.4.4).

Their data show that RFP-KDEL fluorescence labels the nuclear

envelope to high levels, and along transverse membranes. Live cell imaging of motile
(corbular) SR boutons in the cell periphery that contain RyR showed longitudinal
movements across Z-line boundaries over the course of several minutes, providing
evidence of longitudinal trafficking once junctional SR proteins have populated sites in
the cell periphery. Although longitudinal trafficking was not explicitly measured in our
experimental system, such protein movements were inferred from the double labeling
studies carried out with CSQ2-DsRed and TRD/delTRD.

Because the ER exit site

marker sec23 is enriched in a similar Z-line pattern in these cells [85] we previously
suggested that longitudinal traffic away form Z-lines might represent a cardiac ERGIC.
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The current studies offer important additional insights into this question. We showed
here that CSQ2-DsRed remains associated with ER tubules that remain distinct from
junctional SR for at least the 48 h that we recorded its location (this distinction extended
to at least 72 h, N. Sleiman and S. Cala, unpublished observations). The mechanism of
smooth ER to junctional SR transition (Chapter 4 Figure 4-8) remains unknown, but
would be consistent with a role of ER exit sites and the reported build-up of sec23
immunofluorescence along Z-lines [85].
Protein synthesis is a prerequisite for cardiomyocyte health, but accelerated
protein synthesis is a marker of cardiac hypertrophic growth. In cardiomyocytes, the SR
plays an important role in contractile Ca2+ handling compared to other cell types, and
therefore is more extensive and complex. In Chapter 4, we observed an apparent
proliferation of ER following CSQ2-DsRed overexpression.

These juxtanuclear

junctional SR sites might play a role in the maintenance of cardiac hypertrophy. The
distance (roughly 1 m) from the nuclear edge is theoretically close enough to serve as
the Ca2+ microdomain hypothesized to support nuclear transcription associated with the
hypertrophic state [66, 190]. In support of this idea, we previously reported that the
Ca2+ that is bound to CSQ2-DsRed in adult cardiomyocytes is sufficient to elicit
localized perinuclear Ca2+ transients, and in neonatal cardiomyocytes is sufficient to
cause hypertrophic growth determined as increased surface area [171]. Thus, these
juxtanuclear rough ER cisternae and tubules might play a role as a localized Ca2+
microdomain to support Ca2+-dependent transcription thought to drive cardiomyopathic
forms of hypertrophy.
6.3 Model of the inner membrane system in the adult cardiomyocyte
Based upon our extensive fluorescence microscopy data using the unique ER
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and SR markers developed in our studies, we propose an overall model of protein
trafficking to junctional SR. The protein markers reflect a series of inner membrane
subcompartments and their cell biological relationships. The most important elements of
our proposed model are as follows:
1.

Junctional SR proteins are synthesized in the nuclear envelope, generally in both
nuclei.

2.

Rough ER is connected to an extensive and plastic smooth ER that connects the
two perinuclear regions.

This smooth ER is comprised of polygonal tubules

between the nuclei, but also includes extensive tubules or cisternae that align
longitudinally.
3.

Population of junctional SR subcompartments arises from longitudinally aligned
smooth ER that circumvents the cell but is also prominently filled via transverselyaligned membranes.

4.

Smooth ER appears to expand with increasing levels of CSQ2-DsRed expression,
and in so doing, shifts junctional SR subcompartments to more peripheral areas of
the cell.
Proteins destined for inclusion into membrane structures are synthesized on

membrane bound ribosomes (rough ER). Critical processes known to occur in rough
ER include signal sequence docking, mRNA translation, protein translocation into the
ER, N-linked glycosylation, and folding. In the adult cardiomyocyte, the predominant
site of junctional SR protein biosynthesis occurs in close proximity to the nucleus,
presumably within the nuclear envelope. Smooth ER can be comprised of tubules and
flattened cisternae that are free of ribosomes.
Sorting of newly-synthesized proteins to their final destinations requires elaborate

88
specializations of the ER such as transitional ER and Golgi. Transitional ER is a major
ER subcompartment, free of ribosomes. Along smooth ER, transitional ER forms sites
of ER exit, from where an ERGIC can form comprised of fused ER-Golgi transport
vesicles and tubules. In cardiomyocytes, the cytoskeletal scaffold is involved in the
proper localization of proteins (e.g. ion channels) to specific domains of the
sarcolemma.

The proper expression of ion channels in the heart is charted by

cytoskeletal components specifically, MTs. Not much is known of how these cargo are
elected and targeted. The extent of MTs involvement and disruption in the localization
or delivery of transmembrane junctional SR was dramatic.

To improve the

understanding of cardiac protein synthesis and trafficking and thus the remodeling that
accompanies cardiomyopathies that we consider involves this subcellular remodeling of
intracellular membranes.

Figure 6-1. Schematic model of junctional SR filling by newly-made junctional SR
proteins. In adult cardiomyocytes (Normal), protein translation into rough ER
membranes occurs in or near the nuclear envelope (NE). Areas exist within the NE
(green ellipses) in which translocon complexes undergo alignment with sarcomeres to
transport jSR proteins radially (vertical blue arrows). Rough ER becomes sheets or
tubules of smooth ER (curved and longitudinal turquoise arrows) that, along with Ztubules, promote an axial filling of jSR puncta (pink circles). A convoluted set of ER
tubules occupy an axis between nuclei (*asterisk). Following high levels of CSQ2DsRed expression and smooth ER accumulation, smooth ER no longer effectively
transitions to jSR sites, leading to a changes in ER and SR membrane partitioning (gray
fill).
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6.4 Conclusions
In cardiomyopathies capable of producing HF, some change in the pathway for
CSQ2 occurs. It can be detected by changes in CSQ2 processing, and its regulation
(perhaps by CK2 phosphorylation in rough ER) may regulate a relative transition of ER
form its contractile role to a more transcriptional and hypertrophic function. Whether
mass redistribution corresponds to SR morphological remodeling, or is regulated at the
level of CSQ2 turnover will be interesting questions for future investigations. It will be
important to establish which of the several possible mechanisms underlie the altered
processing of CSQ2 in the myocardium, as these in vivo data may add significant
insights into adaptive changes in junctional SR physiology and Ca2+ homeostasis in the
heart.
Changes in TRD and JCT accumulation occurring in cardiomyopathies show the
value of understanding the protein trafficking pathways accompanying the biosynthesis
of functional SR membranes. This study demonstrates a novel biosynthetic pathway in
adult cardiomyocytes.

We show that junctional SR Ca2+-release complex protein

components arrive at junctional SR proximately following synthesis at juxtanuclear
rough ER sites. Disruption of the normal trafficking cycle along with altered cellular
localization could account, in part, for select cardiomyopathies and changes in Ca2+
homeostasis.
Knowledge of pathways leading to functional ER subcompartmentation will
provide a basis for identifying new mechanisms by which protein glycosylation and
phosphorylation, and thus trafficking, lead to changes in functional Ca2+ release sites.
Future studies should focus on understanding the regulatory mechanisms in cardiac
membrane trafficking changes that occur in disease states, which may be either
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adaptive or maladaptive.
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Figure
A-1.
Levels
of
endogenous rat CSQ2 and JCT
proteins at various time points in
culture.
Primary
adult
rat
cardiomyocytes were harvested
after 16, 24, 36 or 48 h (A)
Amido
Black
stained
nitrocellulose
membrane
of
protein extracts from cultured
cardiomyocytes treated with
Ad.JCT (+) or non-treated (-) run
on Bis-Tris MIDI gel (10 %) (B)
Immunoblot of CSQ2rat using
anti-CSQ2rat (C) Immunoblot of
JCT detected using anti-JCTrat.

Figure A-2. Time course of
del
TRDdog
accumulation
at
junctional SR sites. Coverslips
containing cardiomyocytes were
removed and fixed following
treatment with Ad.delTRDdog for
18 and 36 h and remaining cells
harvested for immunoblotting.
(A-C)
Immunofluorescence
TRDdog (red) and nuclei (blue) at
different time points, cells were
stained with anti-TRDdog. Scale
bar 10µm.
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Figure A-3. The effect of nocodazole concentration and duration of treatment.
Immunofluorescence performed on adult rat cardiomyocytes treated with nocodazole as
indicated, fixed and stained with anti-JCTdog (red) after 48 h in culture. (A)
Cardiomyocyte expressing JCTdog and treated with nocodazole for 2 h (B)
Cardiomyocyte expressing JCTdog and treated with nocodazole for 12 h (C)
Autoradiograms of immunoblot performed on protein extracts from cardiomyocytes
treated with Ad.JCT for 48 h either with or without 20 M nocodazole for 36 h showing
JCTdog and α-tubulin levels.
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Figure A-4. Junctional SR sites
distribution depicted by CSQ2rat
endogenous protein localization upon
nocodazole
treatment.
Cultured
cardiomyocytes co-stained with antiCSQ2rat (red) and anti-α-tubulin
(green). (A) Cardiomyocyte without
nocodazole treatment (A1) α-tubulin,
green channel from panel A (A2) red
channel from panel A showing
CSQ2rat (B) Cardiomyocyte treated
in culture with nocodazole (20 M)
(B1) α-tubulin, green channel from
panel B (B2) red channel from panel
B showing CSQ2rat.
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Junctional SR is an important and unique ER subdomain in the adult myocyte
that releases Ca2+ through the actions of an exclusive set of resident proteins. Cardiac
calsequestrin

(CSQ2)

glycosylation on

316

undergoes

two

co-translational

modifications:

N-linked

Asn, and phosphorylation by protein kinase CK2 on a cluster of 3

serines in its tail. In the heart, CSQ2 molecules undergo extensive mannose trimming
by ER mannosidase(s), a posttranslational process that often regulates protein
breakdown.

To investigate CSQ2 protein processing in cardiomyopathy models,

studies were performed to test whether CSQ2 glycan structures would be altered in
heart tissue from mongrel dogs induced into heart failure (HF) by two different
experimental

treatments,

rapid

ventricular

pacing

or

repeated

coronary

microembolizations. CSQ2 mRNA and protein levels were determined, and its
processing was analyzed by electrospray mass spectrometry.

Despite the different

cardiomyopathies producing the failure, roughly one-third of CSQ2 molecules from each
of the failed tissues contained glycan structures indicating a buildup of newly made
protein with highly reduced glycan trimming.

Analyses of tissue samples showed

120
decreases in CSQ2 protein levels per unit levels of mRNA for tachypaced heart tissue,
also indicative of altered turnover.
To place these data in context of junctional SR cell biology, we carried out a
series of studies on primary rat cardiomyocytes to understand the basic features of
junctional SR protein trafficking. We expressed canine forms of junctin (JCT), triadin
(TRD) and CSQ2 in adult rat cardiomyocytes, each a major protein component of the
Ca2+ release complex. Two additional reagents employed were CSQ2-DsRed, which
fails to leave sites of early synthesis due to immediate polymerization, and so was able
to bind TRD and JCT in rough ER; and a deletion mutant of TRD (delTRD) which was
not so affected, and allowed us to directly probe the differences between ER and SR by
double labeling. A complex picture emerged, in which all junctional SR proteins are
synthesized in the nuclear envelope but travel across MT linked smooth ER to
continuously deposit junctional SR proteins. The data suggest that ER proteins traffic
radially along Z-lines, and axially between nuclei, maintaining junctional SR protein
levels through sorting and selective retention as ER traverses Z-lines. ER protein traffic
requires intact MTs, as nocodazole treatment led to loss of anterograde JCT and TRD
traffic away from the nuclear envelope.
We conclude that altered processing of CSQ2 may be an adaptive response to
the myocardium under stresses that are capable of inducing heart failure. We provide a
model of ER and SR protein transport across the cardiomyocytes, and a new
understanding of pathways by which cellular Ca2+ handling protein complexes can be
maintained and modified.
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